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ABSTRACT 
The genetics of isolated colonic Crohn’s disease place it approximately midway between 
Crohn’s disease with small intestinal involvement and ulcerative colitis, making a case for 
considering it as a separate condition. We have therefore systematically reviewed its 
epidemiology, pathophysiology, and treatment.  Key findings include a higher incidence in 
females (65%) and older average age at presentation than Crohn’s disease at other sites, a 
mucosa-associated microbiota between that found in ileal Crohn’s disease and ulcerative 
colitis, no response to mesalazine, but possibly better response to anti-TNF than Crohn’s 
disease at other sites. Diagnostic distinction from ulcerative colitis is often difficult and also 
needs to exclude other conditions including ischaemic colitis, segmental colitis associated 
with diverticular disease and tuberculosis. Future studies, particularly clinical trials, but also 
historical cohorts, should assess isolated colonic Crohn’s disease separately. 
 
INTRODUCTION 
 
Diagnosis of Crohn’s disease is often contentious when ileal involvement is lacking. This has 
a long history. Colitis with skip lesions and rectal sparing was considered in 19301 as 
“regional migratory ulcerative colitis”. Crohn’s classic 1932 paper did not include cases with 
colonic involvement2 although non-tuberculous granulomatous involvement of ileum and 
colon had been reported in 19233 and later by others.4, 5 From the 1930’s to the 1950’s, 
colitis without rectal or terminal ileal involvement was usually designated “regional” or 
“segmental” colitis.6  
 
The British surgeon Wells first used “Crohn’s disease of the colon” when describing cases of 
granulomatous regional colitis in 1952.7 Initially this was not widely accepted and Kirsner 
(1960) continued to refer to cases with submucosal granulomata and skip lesions as 
ulcerative colitis.8 Identification of Crohn’s disease of the colon separately from ulcerative 
colitis was strongly reinforced by Lockhart-Mummery and Morson, (1960) who described 25 
cases with features including non-bloody diarrhoea, anal fistulae, rectal sparing, skip lesions 
and strictures.9 Histopathology showed submucosal giant cell granulomata, fibrous 
thickening, and regional lymph node enlargement. This paper caused a “paradigm shift” that 
has led practice since. It was reinforced the following year when Cornes and Stecher 
reported 45 patients with isolated colonic Crohn’s disease, with fistulation in nearly two 
thirds, and skip lesions in 20% .10  
 
Later evidence that colonic Crohn’s disease, unlike ulcerative colitis, might be improved by 
faecal diversion,11, 12 treatable by segmental resection13, and associated with poor outcomes 
after ileal pouch-anal anastomosis,14 seemed to confirm even more securely its position as a 
form of Crohn’s disease and distinct from ulcerative colitis.  
 
Distinction of colonic Crohn’s disease from ulcerative colitis may be difficult though. The 
term “indeterminate colitis” was introduced to describe cases, “10-20%”, where, after 
colectomy and examination of the resected colon, a clear diagnosis is not possible.15 The 
term was often incorrectly applied to patients without colectomy until “inflammatory bowel 
disease unclassified” (IBD-U) was recommended for such cases.16 
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The scene is now changing again – extensive data show that isolated colonic Crohn’s disease 
is genetically separable from Crohn’s disease involving the small intestine.17 When the ratio 
of Crohn’s-associated genes to ulcerative colitis-associated is compared with disease 
phenotype isolated colonic Crohn’s disease lies approximately midway between ileal 
Crohn’s and ulcerative colitis. IBD-U, although statistically separable from ulcerative colitis 
overlaps it considerably and ileo-colonic Crohn’s disease similarly overlaps ileal Crohn’s 
disease (Figure 1). This finding led to recommendation that Crohn’s disease with ileal 
involvement (ileal and ileocolonic), isolated colonic Crohn’s disease and ulcerative colitis 
should be considered as three separate conditions.  
 
It is therefore timely to review the epidemiology, genetics, serology, microbiology, and 
response to treatment of isolated colonic Crohn’s disease and to reconsider whether this 
“evidence” favours isolated colonic Crohn’s disease as a variant of Crohn’s disease, as a 
variant of ulcerative colitis, or as a separate condition.  
 
METHODS 
The medical literature was searched using National Library of Medicine/Pubmed to 1st 
December 2015 using the terms “colonic and Crohn’s” “Crohn’s and colitis” “epidemiology 
and Crohn’s”. We conducted additional searches for “smoking and Crohn’s disease” and 
“oral contraception and Crohn’s”. Later (to 1st June 2016) additional searches for “Crohn’s” 
and each of the therapies covered were performed. After removal of duplicates and 
screening of abstracts for relevance, 840 were selected for further review (Supplementary 
Figures 1 &2). Whilst the literature search was fully systematic, the subject of this review is 
necessarily much broader than that of a conventional systematic review. We have only 
included full publications in english language and have not attempted to judge quality of the 
data. For epidemiological studies we included all reports that (a) contained data on at least 
100 patients with Crohn’s disease and (b) included separate data for isolated colonic 
Crohn’s disease (Montreal classification L2). Where published studies had overlapping 
patient base and time period we used only the more completely described data set to avoid 
duplication. For other aspects of the review (genetics, serological testing, response to 
therapies and association with environmental factors) we included all studies that identified 
isolated colonic Crohn’s disease separately. For therapeutic studies we have separately 
identified data that have been obtained from randomized clinical trials and those that have 
been obtained from cohort studies. It should be noted that, whereas pure ileal Crohn’s and 
pure colonic Crohn’s should be readily distinguished by a comprehensive diagnostic 
assessment including ileal intubation, incomplete assessment could mislabel ileocolonic as 
colonic. This should be taken into account particularly in respect of older studies but we 
have taken care to ensure that all data included here regarding isolated colonic disease 
relate to patients thought at the time of publication not to have ileal disease. Statistical 
analysis was performed using StatsDirect3 v 3.0.171 StatsDirect Ltd, UK. 
 
PATHOLOGY, DIFFERENTIAL DIAGNOSIS, AND DISEASE COURSE – DEFINING THE 
CONDITION 
The histological features of isolated colonic Crohn’s disease were first defined by Lockhart-
Mummery and Morson.9 They labeled patients with this diagnosis because “they had the 
same characteristic pathology in the large intestinal lesions as that described by Hadfield18 
for the disease as it affects the small intestine”. Gross appearances of the colon following 
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colectomy include less sharp demarcation of ulceration than typically seen in ulcerative 
colitis and with areas of intact intervening mucosa. In some cases, very marked fibrous 
thickening with associated stricturing was present. Fibrosis and oedema sometimes 
extended into the pericolic fat and enlargement of regional lymph nodes was marked. 
Warren later split the macroscopic features into three patterns: isolated rectal disease; 
stricturing colonic disease; diffuse colitis – usually with rectal sparing, and noted that 
approximately 75% develop perianal pathology during their disease course.19 
 
Microscopic features described by Morson included discontinuous inflammation and 
ulceration which could extend into the submucosa or deeper into the wall as the basis of 
fistula formation, plus focal crypt irregularity. Non-caseating epithelioid granulomas were 
present in the majority, distributed through all layers of the bowel wall as well as regional 
lymph nodes. Other features included submucosal lymphangiectasia and neuromatous 
hyperplasia.20 It has subsequently been noted that the earliest lesions – aphthous ulcers – 
which usually overlie lymphoid follicles, are preceded by a “red ring” sign on colonoscopy, 
biopsy of which reveals a lymphoid follicle surrounded by reactive hypervascularisation.21 
 
Histopathology alone is diagnostic only in the minority – in a series of 103 cases of Crohn’s 
colitis, diagnosis was determined by microscopy alone in 28%, by distribution (rectal sparing 
and/or discontinuity) alone in 22% and by combination of the two in 50%.22 Particularly 
discriminatory features suggesting Crohn’s colitis rather than ulcerative colitis include 
granulomata, submucosal inflammation, and relative preservation of goblet cells.23,24 At an 
international workshop expert pathologists “correctly” identified only 64% of cases with 
Crohn’s colitis and 74% with ulcerative colitis25 leading the European consensus on 
histopathology of inflammatory bowel disease (2013) to note that “accurate discrimination 
between the two diseases (Crohn’s colitis and ulcerative colitis) is not yet optimal amongst 
expert gastrointestinal pathologists”. Given that inflammatory disease pathogenesis is 
multifactorial an alternative interpretation would be that there is a continuous phenotypic 
spectrum that runs through from “typical” ulcerative colitis, through IBD-unclassified to 
“typical” Crohn’s colitis.  
 
Early studies reported an additional incidence peak of Crohn’s disease in the elderly 
resulting from cases particularly affecting the sigmoid colon.26 Following the later 
clarification of segmental colitis associated with diverticular disease (SCAD) this seems 
probably attributable to SCAD. SCAD can be indistinguishable histologically from 
inflammatory bowel disease and includes a “Crohn’s-like” variant with granulomata.27 This 
reflects emphasis often placed on the diagnostic specificity of the granuloma. However, 
granulomas are only found in colonoscopic biopsies at diagnosis in about 66% of adults with 
colonic Crohn’s disease, falling to 18% at follow-up.28 Moreover granulomas, particularly in 
association with crypts, can be found in ulcerative colitis.29 Other forms of colitis that may 
need to be considered in the differential include ischemic colitis (see earlier) and infections 
including amoebiasis and tuberculosis but it is beyond the scope of this review to consider 
these further. 
 
Localisation of disease to the colon remains fairly constant over time. The largest published 
data set by far is the 16,902 Crohn’s disease cohort, including 2,933 with isolated colonic 
disease, in the recent genotype/phenotype association study.17 This confirmed previous 
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reports of low rates of progression to ileo-colonic disease (5-14% over 7-10 years). 30-32 
Although luminal narrowing is common, stricturing (B2 disease) as defined in the 
Vienna/Montreal classifications requires the presence of prestenotic dilatation or 
obstructive signs or symptoms and this very rarely occurs, eg 0/45 cases in a Belgian series 
33 whereas penetrating disease (B3) as defined by the Vienna classification (ie including peri-
anal fistulae) occurred in 23% in the same series, less frequently than in patients with ileal 
disease (46%; P=0.0003) or ileocolonic (28.6%; NS). The much larger genotype/phenotype 
association study confirmed that cumulative probability of progression to B2 and B3 
combined over ten years was substantially lower in colonic disease – 23%, than in 
ileocolonic disease - 62%, or ileal disease - 68%.17 The risk of surgery (discussed later) was 
also much lower at ten years (22%) than for ileo-colonic (42%) or ileal disease (62%). A 
recent meta-analysis showed that colon cancer risk in isolated colonic Crohn’s disease is 
similar to ulcerative colitis of equivalent extent with a pooled standardized incidence ratio 
(SIR) of 1.7; 0.9-2.6 95%CI (population based data) compared with SIR 1.8; 1.2-2.4 for 
ulcerative colitis but rising to SIR 18.2; 7.8-35.8 for extensive colonic Crohn’s disease in a 
referral centre population compared with SIR 21.6; 15.0-31.0 for extensive ulcerative 
colitis.34 
 
EPIDEMIOLOGY 
Changes over time 
Studies reporting sequential data from a single centre or region show interesting time 
trends. Studies from UK35,36 and Sweden37 reported a marked increase in isolated colonic 
Crohn’s as a proportion of total Crohn’s from 1970 to 1990 (Figure 2A) whereas later 
studies, particularly from France38 have shown a downward trend since 1990. When looked 
at across all geographical areas, (Table 1), although there is no obvious difference in 
proportion of isolated colonic disease between countries or regions, there is a similar time 
trend with increase in isolated colonic disease between 1960 and 1990, peaking at an 
average of about one third of all Crohn’s disease cases, and decreasing since (p=0.02 by 
polynomial regression, Figure 2B).  
 
Sex variation 
We found eight studies which stated the sex distribution of patients with isolated colonic 
Crohn’s disease. In all but one the female preponderance was equal or greater to that 
reported from the same study for total Crohn’s disease (Table 1) – isolated colonic Crohn’s 
disease averaging 65.1% female, compared with Crohn’s disease excluding isolated colonic 
55.3% female (P=0.027 by paired t test). 
 
Age at diagnosis 
Age at diagnosis of isolated colonic Crohn’s disease (in seven studies; Table 1), has a median 
between 28 and 45, around 10 years older than generally reported for all Crohn’s – eg 
median 25 years in the 16,902 patients studied by Cleynen et al17. Older age of isolated 
colonic versus other sites of Crohn’s disease was also confirmed by the IBDchip European 
Project.85 The preponderance of isolated colonic disease amongst children with very early 
onset Crohn’s disease is discussed later. 
 
Smoking 
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Cigarette smoking is associated with increased risk for development and progression of 
Crohn’s disease but reduced risk for ulcerative colitis. Smoking is more strongly associated 
with risk for ileal and ileo-colonic Crohn’s disease than for isolated colonic disease (Table 2). 
Only one study (of nine)79 reported a higher rate of smoking amongst patients with isolated 
colonic Crohn’s disease. If the South African data84 which reported exceptionally high rates 
(73%) across all groups are excluded, the other studies report rates for smoking amongst 
patients with isolated colonic disease that averaged 37.8% compared with 49.8% (P=0.008 
by paired t test) for other Crohn’s disease sites. This smoking rate is probably slightly higher 
than for the general population – approximately 30% European adults were smokers in 2008 
(WHO).86 
 
Smoking worsens prognosis of Crohn’s disease overall and cessation of smoking improves 
it.87,88 This has been studied less in isolated colonic disease but the conclusion is similar. The 
largest study80 included 688 patients with Crohn’s colitis, 978 with ulcerative colitis and 118 
with “indeterminate” colitis. Sixty-one per cent of patients with ulcerative colitis or 
indeterminate colitis had stopped smoking before disease onset compared with only 12% in 
isolated colonic Crohn’s disease. In women but not men with isolated colonic disease the 
risk of needing immunosuppression was increased amongst smokers (10-yr cumulative risk 
48% in non-smokers vs 58% in smokers, P<0.01). An earlier study74 showed that smokers 
with Crohn’s colitis relapsed approximately 50% more often (P=0.028) and with more pain 
(P<0.007) than non-smokers.  
 
Thus smoking at best has a neutral effect on isolated colonic Crohn’s disease but more likely 
is harmful. 
 
 
Oral contraception 
Meta-analysis of 14 studies, with adjustment for smoking, showed a relative risk of 1.51 
(95%CI 1.17-1.96, P=0.002) for Crohn’s disease amongst women currently taking oral 
contraception89. The relative risk for ulcerative colitis was also increased at 1.53 (1.21-1.94, 
P=0.001). Six of the seven studies that reported risk associated with oral contraception 
separately for isolated colonic disease found a significant association (Table 3) with 
relatively high odds ratio (2.63), risk ratios (3.6 and 3.23) or hazard ratio (4.13). The sole 
exception91 only included 8 cases with isolated colonic Crohn’s disease and showed no 
overall association between oral contraception and risk for Crohn’s disease. Excluding the 
latter study91, five of the other six show higher risks amongst oral contraceptive users for 
isolated colonic Crohn’s than for other sites. 
 
Oestrogen-associated ischaemic colitis as a confounder 
 
An early study from Birmingham50 reported patients with apparent oral contraceptive-
associated colonic Crohn’s disease who had non-granulomatous colitis with rectal sparing.  
Ischaemic colitis is a rare but recognized complication of oral contraception that might 
cause diagnostic confusion. 97,98,99 Most cases have a short duration with typical features of 
ischaemic colitis including abdominal pain, and rectal bleeding. Colonoscopy shows mucosal 
friability but no linear ulceration and the proximal colon and rectum are typically normal. 
Such cases should be readily distinguishable from colonic Crohn’s disease but Tedesco100 
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reported five cases of oral contraceptive-associated colitis with features that overlapped 
more with colonic Crohn’s disease than ischaemic colitis. Moreover, colonic 
“thumbprinting”, a characteristic feature of ischaemic colitis, has been reported in Crohn’s 
disease.101 It is unclear whether diagnostic overlap with milder cases of oral contraceptive-
associated ischaemic colitis contributes to the female preponderance of isolated colonic 
Crohn’s disease. If it does then the change to lower oestrogen dosing in later versions of the 
contraceptive pill might be a plausible explanation for the apparent fall off in cases in recent 
decades.102 Clinicians should be aware of the possible associations between oral 
contraception and inflammatory bowel disease or ischaemic colitis and advise patients 
accordingly – such advice should usually include at least a temporary cessation of oral 
contraception to assess impact on the colitis. 
 
GENETICS 
The strongest genetic association with IBD is the link between NOD2/CARD15 and Crohn’s 
disease. Meta-analysis of 42 studies showed that this association was stronger for Crohn’s 
disease with small bowel involvement than for those without (OR 2.53; 95%CI 2.01-3.16).103 
Subsequent study of 1528 patients with Crohn’s disease from 8 centres (in 7 European 
countries) (IBDchip) confirmed the association of NOD2/CARD15 with ileal involvement and 
also showed that Interleukin23 receptor polymorphisms were more strongly associated with 
isolated colonic Crohn’s (OR 2.20; 95%CI 1.17-4.57).85  
 
The most consistent genetic link with ulcerative colitis is with the rare Major 
histocompatibility Complex (MHC) / Human Leucocyte Antigen (HLA) Class II allele HLA-
DRB*0103. This occurs in less than 2% in European and white North American populations 
and is absent in the Japanese. It is strongly associated with colonic Crohn’s disease where it 
is present at up to 32% frequency with Odds Ratios for isolated colonic disease of 5.1-18.5 
compared with Crohn’s disease at other sites.104 
 
The largest study to compare genetic associations with Crohn’s disease phenotype included 
19713 patients from 49 centres across 16 countries in Europe, North American and 
Australasia.17 This confirmed that the strongest association with isolated colonic Crohn’s 
disease was HLA-DRB1*01:03 (p=1.47 x 10-23, ileal vs colonic OR 0.32, 95%CI 0.29-0.41; 
ileocolonic vs colonic OR 0.47, 95%CI 0.39-0.57). The only other loci that were significant 
across all analyses in this study were NOD2 (16q12), again associated with increased risk for 
ileal involvement (OR ileocolonic vs colonic 1.61,1.59, and 1.89 for the three NOD2 
polymorphisms tested) and also MST1 (macrophage stimulating -1 that encodes a protein 
which induces macrophage phagocytosis) polymorphisms which were more weakly 
associated with ileal involvement (OR 1.07 -1.10 according to polymorphism and whether 
comparing ileal or ileocolonic with colonic disease). When overall genetic risk scores for 
Crohn’s disease and ulcerative colitis were computed as a ratio and compared with 
phenotype, isolated colonic Crohn’s disease was found to be approximately “balanced” in 
respect of Crohn’s disease versus ulcerative colitis genetic risk factors (Figure 1). It was 
found though that even the combination of smoking status with the strongest genetic 
predictors could only explain 6.8% of the variance for disease location.  
 
ISOLATED COLONIC CROHN’S DISEASE IN CHILDHOOD AND SINGLE GENE DISORDERS 
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Amongst children with very early onset Crohn’s disease there is a marked preponderance of 
cases with isolated colonic disease eg 76.5% before age 5105 and 42% before age 8.106 
Amongst younger cases there is a strong male preponderance – eg 1.6:1 across all Crohn’s 
disease presenting <5105 and some of this is accounted for by X-linked single gene disorders. 
The first such condition to be identified was X-linked Chronic Granulomatous Disease.  
Chronic Granulomatous Disease is associated with defects in neutrophil function leading to 
skin lesions and in around 40% with a form of inflammatory bowel disease that is 
indistinguishable from Crohn’s disease, typically with predominant colorectal and perianal 
involvement .107 It is due to mutations in one of four NADPH oxidase complex component 
genes of which the commonest (CYBB) located on the X chromosome accounts for about 
65% cases.   
 
Rapid developments in DNA sequencing have allowed identification of over 50 further single 
gene disorders that present as inflammatory bowel disease, typically as colonic disease and 
with presentation before age 6, defined as Very Early Onset IBD or VEO-IBD.108 VEO-IBD 
cases account for 4-10% of paediatric inflammatory bowel disease.109 One of the commoner 
single gene variants is in the coding region of X-linked inhibitor of apoptosis protein (XIAP) 
that accounts for about 4% of male patients with paediatric onset Crohn’s disease.110 
 
 
SEROLOGY INCLUDING ANTI-MICROBIAL AND ANTI-NEUTROPHIL ANTIBODIES 
Anti-microbial antibodies such as Anti-Saccharomyces cerevesiae (ASCA) and antibodies to 
outer membrane protein (ompC) are found less often and/or at lower titre in isolated 
colonic Crohn’s than in other Crohn’s phen types.111 Meta-analyses confirm this particularly 
for ASCA.112-114 Average sensitivity of ASCA for isolated colonic Crohn’s disease diagnosis is 
31% but with a wide range (8-59%) and an average 14% positivity rate in ulcerative colitis 
(Table 4).  The clinical utility of ompC antibodies has been less studied but reported 
positivity/sensitivity in isolated colonic Crohn’s disease is substantially lower than that for 
ASCA. 
 
Anti-neutrophil antibodies, particularly an atypical peri-nuclear antibody (pANCA), are 
present in around 55% of patients with ulcerative colitis114 and 23% of patients with isolated 
colonic Crohn’s disease (Table 4). This compares with pANCA positivity of around 11% in 
Crohn’s disease overall and 3% in non-IBD controls.114 
 
A combination of positive ASCA and negative pANCA is more discriminatory eg positivity 
rate in isolated colonic Crohn’s disease of 52% compared with 9% in ulcerative colitis122 but 
is still insufficiently predictive for routine clinical use.125 
 
Thus the frequency in isolated colonic Crohn’s disease of both ASCA and pANCA antibodies 
lies somewhere in between that found in Crohn’s disease with ileal involvement (more likely 
ASCA+, and pANCA-) and that found in ulcerative colitis (more likely ASCA- and pANCA+).  
 
 
MICROBIOTA 
The faecal microbiota in active inflammatory bowel disease is commonly dysbiotic with 
reduced bacterial diversity.126,127 This could be secondary to inflammation yet still significant 
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in maintaining chronicity. The large study of pre-treatment Crohn’s disease by Gevers 
showed only a mild dysbiosis in the faecal microbiota and much greater separation of 
Crohn’s disease from healthy controls when the mucosa-associated microbiota was 
studied.128 Ileal and rectal mucosal samples typically showed a reduction in Firmicutes such 
as Faecalibacterium prausnitzii and an increase in Proteobacteria such as Escherichia coli as 
well as in Veillonella, Haemophilus and Fusibacteria. This confirmed many previous studies 
sh wing an increase in mucosa-associated E. coli in Crohn’s disease as well as several 
showing a reduction in F. prausnitzii129-132.  
 
The faecal and mucosa-associated microbiota in isolated colonic Crohn’s disease are 
generally closer to that of healthy controls than is found in patients with ileal or ileocolonic 
Crohn’s disease (Table 5). Thus Baumgart et al129 found that an increase in ileal mucosa-
associated E. coli and reduction in ileal F. prausnitzii was only present in patients with 
Crohn’s disease who had ileal involvement and not in those with isolated colonic disease. 
Similarly, a study of twins with/without Crohn’s disease showed that faecal microbial 
diversity was only reduced and Proteobacteria increased in patients with ileal involvement 
and not in patients with isolated colonic disease.130 A previous report by the same group 
also showed a reduction in F. prausnitzii in Crohn’s patients with ileal involvement but not in 
isolated colonic disease.131 Both the twin study by Willing131 and the large study in 
children128 and adolescents134 did however show differences between the mucosa-
associated microbiota in isolated colonic Crohn’s disease and ulcerative colitis. 16sRNA 
pyrosequencing of mucosal samples133 confirms the increase in E. coli and reduced F. 
prausnitzii in Crohn’s disease with ileal involvement with milder changes in isolated colonic 
disease, although the latter did show some reduction in F. prausnitzii compared with 
healthy controls. This study also confirmed that the mucosa-associated microbiota are 
consistent at different sites from ileum to rectum in the same individual. 
 
In conclusion, mucosa–associated microbiota changes in Crohn’s disease are more marked 
than faecal changes. The microbiota in isolated colonic Crohn’s disease, show changes that 
tend to be less marked and less consistent than those found in Crohn’s disease with ileal 
involvement. 
  
 
 
RESPONSE TO TREATMENT 
 
Mesalazine 
 
Systematic reviews show no convincing benefit of oral mesalazine (5-aminosalicyclic acid) 
over placebo either in induction of remission or in maintenance of medically induced 
remission in Crohn’s disease as a whole1345138 although they may have a modest benefit in 
maintaining surgically-induced remission.139 Sulphasalazine (sulphapyridine linked via azo 
bond to 5-aminosalicylate) has possible modest efficacy in induction of remission.134, 136 
 
Amongst trials that have reported data separately for isolated colonic Crohn’s disease, only 
one trial studied the effect of oral mesalazine in remission induction140 and four studied its 
effect in maintenance of medically-induced remission141-144 (Table 6). In none of these was 
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mesalazine significantly more effective than placebo but in two studies141,142 there was a 
weak signal suggesting a better response in ileal disease. A single trial of olsalazine showed 
worse results than for placebo, probably because of drug-related diarrhea.145 Sulphasalazine 
was no better than placebo in two trials of maintenance146,147 but there was a weak signal of 
efficacy in remission induction in two trials147,148 but these only studied 17 and 27 patients 
with isolated colonic disease respectively (including placebo). Apart from case reports there 
have been no published studies of rectal mesalazine in isolated colonic Crohn’s disease. 
 
It can be reasonably concluded that mesalazine and olsalazine do not have efficacy in 
isolated colonic Crohn’s disease. Sulphasalazine possibly has some efficacy in remission 
induction. 
 
Antibiotics 
 
Systematic reviews suggest a beneficial effect for antibiotics in the induction of remission 
for Crohn’s disease though these have included diverse antibiotics and small trials.149-151 The 
largest study to date is for rifaximin.152 Three doses were tested: 400, 800, 1200mg or 
placebo twice daily for 12 weeks with good efficacy overall but no dose response. Amongst 
patients with isolated colonic disease higher remission rates (51%) were found for rifaximin 
(pooled doses) than for placebo (37%) and efficacy was better in this group than for other 
disease sites (Table 7). 
 
Metronidazole has also shown better efficacy in isolated colonic Crohn’s disease but based 
on very small numbers (Blichfeldt153: n=6 crossover; Sutherland154: 8 active and 4 placebo). 
In a study of 134 patients randomly assigned to ciprofloxacin and metronidazole, both 
500mg twice daily, or placebo in combination with budesonide 9mg daily155 a trend was 
seen towards benefit in patients with colonic involvement compared with those without but 
separate data were not reported for patients with isolated colonic disease. A large 
randomized trial of long duration (up to 2 years) antibiotic therapy (clarithromycin, rifabutin 
and clofazimine) targeted against Mycobacterium avium paratuberculosis in patients also 
receiving tapered prednisolone showed short term efficacy with 66% active in remission at 
16 weeks compared with 50% placebo  (P=0.02) and 39% relapsed by 12 months compared 
with 56% placebo (P=0.054).156 No differential response was seen according to disease 
location but data were not presented separately for patients with isolated colonic disease. 
Rifaximin and metronidazole thus show some evidence of efficacy in patient with isolated 
colonic Crohn’s disease and antibiotics tend to perform better in this group of patients than 
in Crohn’s disease at other sites but based on very small data sets. Further trials are clearly 
needed. 
 
Corticosteroids 
 
Given the widespread use of corticosteroids in Crohn’s disease the quality of evidence for 
their efficacy is surprisingly poor. There have only been two placebo-controlled trials of 
standard glucocorticosteroids.147,148 Each of these included only 8 steroid-treated patients 
with isolated colonic disease (Table 8) with one trial147showing no benefit and the 
other148showing efficacy. There has never been a trial to assess dose-responsiveness to 
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conventional corticosteroids in Crohn’s disease so optimal dosage is unknown. More data 
are available for budesonide but trials have focused predominantly on patients with ileal or 
ileo-colonic disease so data in isolated colonic disease are again very sparse. The data from 
one comparison with mesalazine157, support efficacy in isolated colonic Crohn’s disease, 
possibly with a weaker effect than conventional corticosteroids158, but reduced 
corticosteroid side-effects. 
 
 
 
Anti-TNF 
 
None of the randomised trials of infliximab159,160 or adalimumab161-164 reported subgroup 
analyses of outcomes based on disease location. In a randomised, placebo controlled trial of 
certolizumab pegol, patients with colonic (OR 2.39, 95% CI 0.99-5.75, P=0.052) and 
ileocolonic disease (OR 2.07, 95% CI 1.01-4.28, P=0.048) were more likely to achieve 
remission at week 6 compared to ileal disease (OR 0.42, 95% CI=0.18-0.99, P=0.048)165(Table 
9) 
 
Several cohort studies have assessed colonic disease location as a predictor of response to 
anti-TNF agents, four with infliximab and one with adalimumab. Three cohort studies 
assessing induction therapy with infliximab166-168 all showed better response rates in 
isolated colonic disease than for disease at other sites. Paradoxically, cohort studies of 
infliximab maintenance in children169 and of adalimumab maintenance in adults170 both 
showed higher risk of lost response or dose escalation in isolated colonic disease. Overall, 
the evidence supports good efficacy for anti-TNF therapy in induction of remission in 
isolated colonic Crohn’s disease but possibly with a higher subsequent rate of loss of 
response. 
Vedolizumab 
In the combined induction and maintenance study of vedolizumab there was no significant 
difference in efficacy in isolated colonic disease compared with other locations.171 (Table 9) 
Enteral nutrition 
Exclusive enteral nutrition is effective as primary therapy in patients with active Crohn’s 
disease172,173 and partial enteral nutrition has shown efficacy in maintenance of remission.174 
In ulcerative colitis total parenteral nutrition and bowel rest are ineffective175 and 
comparison of enteral with parenteral nutrition showed no difference in efficacy176 implying 
no efficacy for enteral nutrition either.  Whether enteral nutrition is effective as primary 
therapy in isolated colonic Crohn’s disease is controversial. Relatively few studies provide 
separate data on patients with isolated colonic Crohn’s disease (Table 10). Five of the six 
studies are in children. Two studies178,179 report poorer results in children with isolated 
colonic disease compared with those with small intestinal involvement. Numbers are small 
though (19 cases of isolated colonic disease across the two trials) and the other studies 
(including 72 cases of isolated colonic disease across four trials) found no significant 
difference in remission rates for those with isolated colonic disease compared with other 
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sites. Further trials of exclusive enteral nutrition are needed in patients with isolated colonic 
disease. 
 
Surgery 
Faecal diversion 
Colonic Crohn’s disease commonly responds to “bowel rest” induced by a defunctioning 
ile stomy whereas ulcerative colitis does not.11, 12 Instillation of unfiltered ileostomy 
contents into the defunctioned colon induced relapse whereas instillation of content that 
had passed through a 0.22micron pore diameter filter did not, implying a role for bacteria in 
pathogenesis.183 Defunctioning ileostomy has become less commonly performed for the 
treatment of uncomplicated colonic Crohn’s disease since it was shown that at least 50% 
relapsed after continuity was restored.184 
 
Resection 
The cumulative risk of surgery for isolated colonic Crohn’s disease is reported as 22-33% by 
10 years after diagnosis compared with around 75-90% for ileal disease.17,67 Partial 
resection, either right hemicolectomy for proximal disease or a segmental resection for 
more distal disease has been shown to be successful therapy for colonic Crohn’s disease185, 
186 as is colectomy with ileo-rectal anastomosis for more extensive disease if the rectum is 
uninvolved187,188. Approximately 75% of patients with ileo-rectal anastomosis will still have a 
functioning anastomosis after 10 years and about two thirds of those treated by segmental 
resection will not have required a further resection.188 Recurrence rates are similar after 
either procedure.189 This contrasts with left-sided ulcerative colitis, where the tempting 
option of left hemicolectomy with right-sided colo-anal anastomosis consistently fails, 
usually with rapid recurrence of colitis in the retained colon.190 It should be noted though 
that segmental resection for colon cancer complicating colonic Crohn’s disease has been 
associated with high (39%) risk for metachronous colon cancer191 suggesting that 
panproctocolectomy might be a safer option for such patients.  
 
Ileo-anal pouch reconstruction 
Crohn’s disease has generally been considered a contra-indication for restorative ileo-anal 
pouch surgery and even in selected patients pouch failure of 57% has been reported from 
the UK.192 Others have suggested that it may be successful in very carefully selected 
patients. Thus, a series of 3,707 patients with ileal-pouch anal anastomosis from the 
Cleveland Clinic included 150 with Crohn’s disease, of whom 32 had a pre-operative 
diagnosis, the remainder diagnosed by post-operative histopathology or on follow-up. 
Amongst 59 patients with Crohn’s disease reaching 10 year follow-up, pouch survival was 
80%.193 Forty nine of 132 patients (37%) needing pouch excision had a histological diagnosis 
of Crohn’s disease. Considering that a pre-operative diagnosis of Crohn’s disease was only 
present in less than 1% of patients receiving pouch-anal anastomosis these data do not 
make a strong case for this procedure in patients with a definite diagnosis of colonic Crohn’s 
disease.  
 
 
CONCLUSION  
Current data suggest that the genetics, microbiota, serology and smoking association of 
isolated colonic Crohn’s disease lie between those of ileo/ileocolonic Crohn’s disease and 
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ulcerative colitis and make a strong case for this phenotype being considered separately 
(Table 11). Genetic data in particular show good separation from ileal/ileocolonic Crohn’s 
disease and the low rate of progression from isolated colonic to ileo-colonic disease help to 
justify this distinction. There is a disappointing paucity of good quality therapeutic data but 
the lack of response to mesalazine, whose target cell is the surface epithelium, suggests a 
different pathophysiology to ulcerative colitis and there are important differences from 
ulcerative colitis in surgical outcomes, including a good response to segmental resection in 
selected cases and a generally poor response to pouch reconstruction. Taken together this 
implies a compelling need for isolated colonic Crohn’s disease to be identified separately 
from ileal/ileocolonic disease and from ulcerative colitis. This is particularly important when 
future therapeutic trials are designed and when cohort studies are reported. 
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LEGENDS TO FIGURES: 
1. Comparison between Crohn’s disease genetic risk score and ulcerative colitis genetic 
risk score for different locations of Crohn’s disease, ulcerative colitis and IBD unclassified 
(from Cleynen et al,17 with permission. This shows that isolated colonic Crohn’s lies 
approximately equidistant genetically between ileal Crohn’s disease and ulcerative 
colitis. 
 
2A. Isolated colonic Crohn’s as percentage of all Crohn’s disease by year in studies 
reporting sequential data from the same centres or geographical areas. 
2B. Isolated colonic Crohn’s disease as percentage of all Crohn’s disease by year in all 
studies. 
 
 
 
Supplementary Files 
1. PRISMA flow diagram.  
2. PRISMA checklist. 
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Authors/ref Country Years 
analysed 
Number 
of 
cases 
all CD 
All CD 
% 
female  
Isolated 
colonic CD 
as % of total 
CD  
Isolated 
colonic 
CD % 
female 
CD 
excluding 
Isolated 
colonic 
% female 
(calculated) 
Median Age 
at 
presentation 
(colonic CD) 
unspecified or 
indeterminate 
as ratio to 
colonic CD in 
same series 
Cornes10 UK 1961 131 46 34 60 38 41-50 - 
Gollop39 USA 1943-
82 
103 64 36 68 62 25-34 - 
Loftus40 USA 1940-
93 
225 54 32 - - - - 
Humphreys41 UK 1966-
81 
440 58 40 - - - - 
Ekbom42 Sweden 1965-
83 
1469 53 25 - - 33 (mean) - 
Kyle35 UK 1955-
88 
856 63 41 63 63 40-49 - 
“ “ “ “ 1964-
69 
122 - 30 - - - - 
“ “ “ “ 1970-
75 
167 - 40 - - - - 
“ “ “ “ 1976-
81 
204 - 46 - - - - 
“ “ “ “ 1982-
87 
263 - 54 - - - - 
Lapidus37 Sweden 1955-
59 
83 61 14 - - - - 
  1960-
64 
145 48 15 - - - - 
  1965-
69 
270 51 21 - - - - 
  1970-
74 
364 53 26 - - - - 
  1975-
79 
331 54 26 - - - - 
  1980-
84 
348 58 32 - - - - 
  1985-
89 
395 49 32 - - - - 
Gunesh36 UK 
(Cardiff) 
1950-
60 
40 - 13 - - - - 
“ “ “ “ 1960-
70 
89 - 17 - - - - 
“ “ “ “ 1970-
80 
148 - 34 - - - - 
“ “ “ “ 1980-
90 
217 - 38 - - - - 
Yapp43 UK (Cardiff) 1991-
95 
84 68 43 - - - - 
Gunesh36 “ “ 1996-
2005 
212 61 43 68 55 - - 
Jayanthi44 UK 1972-
89 
235 50 25 
(incr from 
1972 to 89) 
- - - - 
Cottone45 Italy 1975-
95 
882 - 18 - - - - 
Jacobsen46 Denmark 1978-
87 
196 67 
(1978-
87) 
32 - - - - 
“ “ “ “ 1988-
97 
354 “ “ 42 - - - - 
“ “ “ “ 1998-
2002 
230 “ “ 51 - - - - 
Wright47 S.Africa 1980-
84 
134 69 27 - - - 0.44 
Manninen48 Finland 1986-
99 
470 50 40% 1986 
31% 1999 
- - - 0.56 
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Economou49 Greece 1983-
2005 
105 37 40 - - - 0.40 
Rhodes50 UK 1984 395 55 22 72 50 28 
(subset) 
- 
Gower-
Rousseau51 
France 1994 674 57 19 - - 28 1.15 
Auvin52 France 1988-
99 
367 
(< 17y) 
47 10 - - - 0.54 
Spanish53 Spain 1997 635 52 17 - - - - 
Jess54 Denmark 1962-
87 
374 58 30 - - - - 
“ “ “ “ 1991-
93 
58 66 43 - - - - 
“ “ “ “ 2003-
04 
209 54 37 - - - - 
Chow55 China 1987-
2005 
109 29 35 - - - - 
Chouraki38 France 1988-
2007 
7409 56 11 - - - 0.90 
“ “ “ “ 1988-
90 
544 - 23 - - - - 
“ “ “ “ 1997-
99 
1044 - 13 - - - - 
“ “ “ “ 2006-
07 
533 - 5 - - - - 
Romberg-
Camps56 
Netherlands 1991-
2003 
476 61 27 66 59 34 (mean) 0.63 
Bjornsson57 Iceland 1995-
2009 
279 54 55 - - - 0.08 
Tozun58 Turkey 2001-
03 
216 44 26 - - - - 
Lakatos59 Hungary 2002-
06 
163 48 36  -   
Nguyen60 USA/Canada 2003-
05 
579 - 19 - - - 0.30 
Ott61 Germany 2004-
06 
168 55 18 - - - 0.43 
Siddique62 Kuwait 2005-6 206 52 14 - - - - 
Chen63 USA 2005-
10 
628 55 21 50 56 - - 
Lucendo64 Spain 2000-
12 
599 49 24 - - - 0.10 
Henckaerts65 Belg 2007 874 - 17 - - - 0.03 
Herrinton66 USA 2008 948 55 40 - - - 0.10 
Hancock67 UK 2008 675 62 20 
(“enriched”) 
74 59 31 (mean) - 
Aloi68 Italy 2009-
13 
10 
(<5y) 
- 50 - - - - 
“ “ “ “ “ “ 215 
(6-18y) 
- 15 - - - 1.00 
Aljebreen69 Saudi 2009-
13 
497 41 8 - - - - 
Burisch70 Western 
europe 
2010 345 48 26 - - - 1.19 
“” “” Eastern 
europe 
2010 99 41 20 - - - 0.30 
Eglinton71 NZ 2011 507 63 42 - - - - 
Ng72 Asia-pacific 2011-
12 
166 Asia 
39% 
Austr 
52% 
24 - - - 0.53 
Cleynen17 16 countries 2015 16,902 56 24 - - - 0.06 
 
 
Table 1. Studies of Crohn’s disease age and sex distribution and proportion of total,  where 
isolated colonic Crohn’s disease separately identified (in approximate median date order). 
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• “current smoking” variably either smoking at time of diagnosis or at time of sampling but excluding “ex-smoking” 
 
Table 2. Studies of smoking in Crohn’s disease where isolated colonic disease separately 
identified 
  
Author/ref Year Country Number of 
cases CD 
Nature of study Current smoking OR/RR for 
CD phenotype 
Current 
smoking * 
isolated 
colonic CD 
% 
Current 
smoking all 
CD% 
Current 
smoking 
CD 
excluding 
isolated 
colonic % 
Current 
smoking 
healthy 
controls % 
Current 
smoking 
UC % 
Somerville73 1984 UK 82 Case control RR for smoking and CD: 
Small bowel only 3.5 (0.8-
14.6) 
Colon only 4.7 (1.4-16.1) 
Small and large bowel 4.5 
(1.8-11.5) 
- 56 - 26 - 
Holdstock74 1984 UK 150 Consecutive 
outpatients 
- 25 
(smokers 
with isolated 
colon CD 
had more 
relapses 
P=0.028) 
35 52 - 8 
Tobin75 1987 UK 137 Case control RR for smoking at onset 
and CD: 
Small bowel only 1.4 (0.5-
4.0) 
Ileum and asc colon 6.0 
(2.1-17.2) 
Small bowel and rest of 
colon 3.9 (1.5-10.2) 
Colon only 2.5 (0.8-7.3) 
- 47 - 33 
(controls 
for UC 
40%) 
11 
Lindberg76 1992 Sweden 231 Postal 
questionnaire 
(95% 
response) 
- 42 51 53 - - 
Breuer-
Katschinski77 
1995 Germany 346 Postal 
questionnaire 
(82% 
response) 
- 49 50 49 - - 
Russel78 1998 Europe 
(20 
centres, 
13 
countries) 
457 Prospective 
consecutive 
cases 
- 35 47 59 - 16 
Cosnes79 1999 France 622 Consecutive 
outpatients 
- 54 49 49 - - 
Cosnes80 2004 France 688 all 
colonic 
Consecutive 
outpatients 
- 61 -  - 42 
Aldhous81 2007 UK 
(Scotland) 
408 Retrospective 
outpatients 
- 33 43 50 - - 
Hancock67 2008 UK 675 Database OR 1.64 (1.09-2.45) for 
never smokers with isolated 
colonic CD vs ileal or 
ileocolonic 
51 
(ever) 
61 
(ever) 
63 - - 
Chen82 2011 USA 628 University 
database 
OR 1.69 (1.07-2.66) for any 
ileal involvement (L1+L3) 
vs colon only (L2) 
25 37 38 - - 
Nunes83 2013 Spain 3224 National 
registry 
- 26 34 35 - - 
Chivese84 2015 S. Africa 194 Prospective 
consecutive 
cases 
RR 3.63 (1.32-9.98) 
for ileo-colonic vs colonic; 
RR 3.54 (1.06-11.83) 
for ileal vs colonic 
62 73 79 - - 
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Author/Ref Study design N (total CD) n/% isolated 
colonic CD taking 
OC at onset 
n/% all other CD 
taking OC at 
onset 
OR/RR (95%CI) for 
OC use compared 
with healthy 
controls (when 
documented by 
disease location) 
OC use in 
isolated 
colonic vs all 
other CD 
Rhodes50 Case control 
matched for 
age and year of 
onset 
37 9/12 75% 11/25  44% - NS Increased 
P=0.09 
 
Vessey90 Cohort study in 
patients 
attending family 
planning clinics 
18 4/7 57% 4/11 36% - NS increased 
0.63 
Lashner91 Case control 51 (incl 8 
isolated colonic) 
- - Isolated colonic  
OR0.50(0.05–5.26) 
 
Small bowel only 
1.25 (0.34–4.64) 
 
Ileocolonic 
0.56(0.20-1.52)  
 
 
NS reduced 
(and no 
significant 
association in 
this study 
between OC 
use and any 
Crohns) 
Sandler92 Case control 
Age matched 
and excluding 
onset before 
menarche 
184 (incl 26 
isolated colonic) 
- - Isolated colonic 
OR2.63 (1.00-7.11) 
 
Small bowel only 
1.33 (0.70-2.53) 
 
Ileocolonic 1.52 
(0.82-2.83) 
NS increased 
Persson93 Case control 
age and sex 
matched 
152 - - Isolated colonic 
RR 3.6 (1.1-12.2) 
 
Small bowel only 
0.8 (0.3-2.4) 
 
Ileocolonic 
1.7 (0.8-4.0) 
NS increased 
Katschinski94 Case control 
pre-
menopausal  
90 
(incl 30 isolated 
colonic) 
- - Isolated colonic 
RR3.2 (1.1-15.3) 
 
Small bowel only 
RR4.7 (1.6-17.8) 
 
Ileocolonic 
RR 3.8 (1.3 -17.0) 
NS reduced 
Khalili95,96 Cohort – 
Nurses Health 
315 (incl 141 
isolated colonic) 
- - Isolated colonic 
HR4.13 (1.77-9.68) 
 
Ileal only 
HR2.99 (1.06-8.49) 
NS increased 
 
Table 3 – Studies of oral contraceptive usage in Crohn’s disease where isolated colonic 
disease separately identified. 
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Author/Ref Year Study design N (isolated 
colonic 
CD) 
ASCA 
IgA 
(n/%) 
ASCA 
IgG 
(n/%) 
ASCA (IgG 
or IgA) 
(n/%) 
pANCA 
(n/%) 
ompC 
(n/%) 
GP2 UC results in same 
study 
Comments 
Duerr115 1991 Prospective  18 - - - 5/18 
(28%) 
- - pANCA 34/40 (85%) pANCA+ in isolated colonic CD 
not signif commoner than  
diarrhea-predom IBS (4/27 
15%) 
Cambridge116 1992 Stored sera 
IBD and 
healthy 
controls 
18 - - - 1/18 
(6%) 
- - pANCA 27/50 (54%) pANCA+ in 4/32 CD with small 
bowel involvt 
Joossens117 2002 Prospective 
follow-up of 
97 patients 
with initial 
diag of 
indeterminat
e colitis 
17 NA NA 10/17 
(59%) 
6/17 
(35%) 
- - ASCA+ in 3/14 (21%) 
pANCA+ in 8/14 (57%) 
All patients initially 
indeterminate 
Lawrance118 2004 Prospective 
Caucasian 
and Chinese 
35 6/35 
(18%) 
9/35 
(26%) 
NA NA - - ASCA IgA 6/100 
ASCA IgG 11/100 
ASCA less likely positive in 
isolated colonic CD than CD 
with ileal involvement 
Annese119 2004 Prospective 61 NA NA 25/61 
(41%) 
- - - ASCA 32/197 (16%) ASCA in CD overall 51% 
Ferrante120 2007 Prospective 
study IBD 
plus non-IBD 
and healthy 
controls 
70 NA 6% NA 21% 3.5% - ASCA IgG 9.6% 
pANCA 37% 
All antimicrobial abs lower titre 
in isolated colonic CD  than 
other CD 
Vind121 2008 Prospective 
cohort 
60 NA NA 5/60 (8%) 15/60 
(25%) 
- - ASCA 14% 
pANCA 55% 
ASCA CD overall 22% 
Lakatos122 2009 Cohort 143 NA NA NA NA - - ASCA(either IgA or 
IgG)+/pANCA- 
combination in 9% UC 
ASCA(either IgA or 
IgG)+/pANCA- combination in 
52% isolated colonic CD 
Bogdanos123 2012 Prospective 
paediatric  
32 NA NA 5/32 (16%) - - 2/32 
(6.2%) 
GP2 9/102 (8.8%) 
ASCA 7/102 (7%) 
GP2 ab (IgG or IgA) in 49/137 
(35.8%) other (nonL2) CD 
ASCA 55/137 (40.1%) other 
(nonL2) CD 
Bertin124 2013 Prospective 
recruited at 
colonoscopy 
67 NA NA 21/67 
(31%) 
- 15/67 
(22%) 
- ompC 2/35 (6%) 
ASCA 5/35 (14%) 
Colon mucosal culture 
supernatant ab measures 
discriminated better between 
L2 CD and UC 
Elkadri111 2013 Prospective 
cohort adults 
and children 
55 NA NA NA but OR 
0.25 (0.12-
0.51; 
P=0.0002) 
for assocn 
with 
isolated 
colonic 
disease vs 
other sites 
NA but 
OR 2.27 
(1.50 – 
4.92; 
P<0.03 
for 
assocn 
with 
isolated 
colonic 
disease 
42.7% all 
CD, 
isolated 
CD NA 
- ASCA (either IgA or 
IgG) in 12.1% UC; 
62.9% CD; 
pANCA in 55.6% UC, 
14.3% CD; 
anti-OmpC in 28.0% 
UC, 42.7% CD 
ASCA positivity less common in 
isolated colonic CD than other 
sites 
 
 
Table 4. Serological test results in isolated colonic Crohn’s disease and ulcerative colitis.  
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*Though the study included patients with isolated colonic CD, results were pooled for patients with colonic involvement 
#Willing 2010, similar patient cohort to Willing (2009) but sequencing methodology compared to terminal-restriction fragment length polymorphism in Willing 
(2009).  
‡FE index was calculated as [log10 (F/Hc) − log10 (E/Hc)/log10 (TB/Hc), F being the 16S rRNA gene copies of F. prausnitzii, E the 16S rRNA gene copies of 
E. coli, Hc a million of human cells, and TB a million of 16S rRNA gene copies of total bacteria.  
 
Table 5: Studies of mucosal microbiota in Crohn’s disease where isolated colonic disease 
separately identified 
  
Author/ref Year Specimen 
type 
Number 
of cases 
CD 
Ileal CD Ileocolonic CD Isolated colonic CD  Ulcerative 
colitis 
Healthy 
controls 
Conclusions 
Naftali133 2016 Ileum and 
colon 
31 15 
Increased abundance 
of Escherichia and  
reduced 
Faecalibacterium; 
disease activity 
correlated with 
abundance of 
Fusobacterium 
8* 
Similar to colonic 
CD apart from 
Faecalibacterium 
abundance 2.7-
fold lower than in 
isolated colonic 
CD (not 
significant) 
 
8* 
Higher levels of 
Faecalibacterium 
and 2 unidentified 
genera of the 
Clostridiales and 
Ruminococceaea; 
lower levels of 
Enterobacteriaceae 
compared with ileal 
NA NA Ileal CD and colonic 
CD microbiomes 
distinct 
 
Haberman13
4 
2015 Ileal 
biopsy 
243 
(Paediat
ric) 
180 
Persistent reduction in Lachnospiraceae, 
Bifidobacteriaceae, Clostridiales, and 
Erysipelotrichaceae in all forms of CD, with 
expansion of Veillonellaceae, 
Pasteurellaceae, Neisseriaceae, 
Gemellaceae, Fusobacteriaceae, and 
Enterobacteriaceae 
 
 
63 
Persistent reduction 
in Lachnospiraceae, 
Bifidobacteriaceae, 
Clostridiales, and 
Erysipelotrichaceae 
in all forms of CD, 
with expansion of 
Veillonellaceae, 
Pasteurellaceae, 
Neisseriaceae, 
Gemellaceae, 
Fusobacteriaceae, 
and 
Enterobacteriaceae 
73 
Increased 
abundance 
of Firmicutes 
phyla 
43 
 
No difference 
between 
ileal/ileocolonic CD 
and colonic CD 
microbiome  
 
Lopez-
Siles132 
2014 Ileum and 
colon 
45 19 
Reduction in F. 
prausnitzii, E. coli 
moderately increased. 
13 
Reduction in  F. 
prausnitzii 
13 
F. prausnitzii 
comparable to UC; 
E. coli commoner 
than UC particularly 
in ulcerated zones 
28 
F. prausnitzii 
abundance 
intermediate 
between CD 
and HC. 
28 F. prausnitzii/ E. coli 
(FE index)‡ allowed 
differentiation 
between ileal CD and 
other CD 
phenotypes. 
Microbiota changes 
in colonic CD 
intermediate 
between ileal CD and 
UC. 
Willing#130,13
1 
2009,
2010 
Ileum and 
colon 
14 6 
Increased 
Enterobacteriaceae 
and  Ruminococcus 
gnavus;  decreased 
Faecalibacteria and 
Roseburia and 
compared to healthy 
controls. Increased E. 
coli. 
 8 
No reduction in 
Faecalibacterium or 
Roseburia. Some 
increase in E. coli 
but less marked 
than ileo-colonic. 
 6 Colonic CD 
microbiome 
intermediate 
between ileal CD and 
healthy controls. 
Baumgart129 2007 Ileum 29 13 
Increased abundance 
of Enterobacteriaceae, 
(E. coli, Shigella) 
reduction in  
Lachnospiraceae, 
(Ruminococci, 
Roseburia and 
Coprococci) and 
Clostridiales ( 
Faecalibacteria and 
Subdoligranula) 
8 
Results not 
presented 
separately 
8 
Enterobacteraciae 
not increased and 
Faecalibacteria not 
reduced. 
NA 7 
 
Ileal CD and colonic 
CD microbiome were 
distinct. Colonic CD 
more closely 
resembled healthy 
controls 
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Author/Ref N (isolated colonic 
CD) 
5ASA Placebo P value Conclusions 
Singleton140 64 CDAI mean change: 
-77 (+/-27) at 2g/day 
-81 (+/-31) at 4g/day 
CDAI mean change 
-52 (+/-31) 
Overall <0.01 for 
mesalazine vs 
placebo in all CD, 
P=0.42 for 
difference in ileal vs 
ileocolonic vs 
colonic 
High placebo 
response rate in 
isolated colonic 
CD so NS if this 
group taken alone; 
better response in 
ileal only disease 
 (a) Placebo-controlled trials of oral 5-aminosalicylic acid in isolated colonic Crohn’s disease 
(i) induction 
 
 
Author/Ref N (isolated colonic 
CD) 
5ASA relapse rate 
12months  
Placebo relapse 
rate 12 months 
P value Conclusions 
International141 56 32.1% 
(9/28) 
38.9% 
(11/28) 
0.49 5ASA only showed 
benefit in ileal 
disease 
Prantera142 18 40% 
(2/5) 
55% 
(6/?11) extrapolated 
from table 
NS 5ASA only showed 
benefit in ileal 
disease 
Gendre143 48 - - - 5ASA better 
(P<0.003) than 
placebo in all CD 
patients in remission 
<3m at onset, no sig 
difference according 
to disease location  
De Franchis144 36 45% 
(8/17)(extrapolated 
from figure) 
45% 
(9/19) 
1.0 5ASA ineffective in 
ileal, colonic, or 
ileocolonic 
 
 
(a) Placebo-controlled trials of oral 5-aminosalicylic acid in isolated colonic Crohn’s disease 
(ii) maintenance 
  
Page 31 of 80
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 32
Author/Ref N (isolated colonic 
CD) 
Sulphasalazine 
remission 
Placebo  
remission 
P value Conclusions 
Singleton146 20 - - NS Both groups also 
received tapering 
prednisolone. 
Placebo better 
than 
sulphasalazine in 
patients with ileal 
disease. 
Summers147 17 - - 0.006 
(comparison of 
outcome ranks) 
Sulphasalazine 
better than 
placebo in colonic 
CD (also effective 
in ileocolonic but 
not ileal only) 
Malchow148 27 31% 
(4/13) 
14% 
(2/14) 
0.4 NS for remission 
but P<0.01 for 
effect when judged 
by “failure and 
relapse” 
 
 (b) Placebo-controlled trials of oral sulphasalazine in isolated colonic Crohn’s disease (i) 
induction 
 
 
Author/Ref N (isolated colonic 
CD) 
Sulphasalazine 
relapse rate 
12months  
Placebo relapse 
rate 12 months 
P value Conclusions 
Singleton146 20 - - NS Sulphasalazine not 
significantly different 
from placebo in CD 
overall and no 
relation to disease 
location  
Summers147 19 - - NS No significant effect 
(judged by outcome 
rank based on 
CDAI) 
 
 
(b) Placebo-controlled trials of oral sulphasalazine in isolated colonic Crohn’s disease (ii) 
maintenance 
 
 
 
Author/Ref N (Isolated colonic 
CD) 
Olsalazine relapse 
/failure rate 12 
months 
Placebo relapse 
/failure rate 12 
months 
P value Comments 
Mahmud145 145 65.4% 53.6% 0.035 (Olsalazine 
worse) 
Olsalazine induces 
diarrhea, no 
evidence of efficacy 
 (c) Placebo-controlled trial of olsalazine in isolated colonic Crohn’s maintenance 
 
Table 6. Trials of 5ASA preparations where data presented separately for isolated colonic 
Crohn’s disease. 
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Author/Ref N (isolated 
colonic CD) 
Comparator Primary end 
point 
Rifaximin remission 
rate 
Placebo 
remission rate 
P value Conclusions 
Prantera152 190 active; 
76 placebo 
(from 
supplement 
table 2) 
Placebo Week 12 
remission 
(CDAI <150) 
3 doses: 400mg bd; 
800 mg bd; 1200 
mg bd; no dose 
response overall;  
pooled doses 
remission in 96/190 
(51%) 
28/76 (37%) 0.04 Rifaximin more 
effective for 
colonic than 
ileal disease 
(a) Controlled trial of oral rifaximin  
 
 
Author/Ref N (isolated 
colonic 
CD) 
Comparator Primary end 
point 
Metronidazole 
response rate 
Placebo 
response rate 
P value Conclusions 
Blichfeldt153 6 Placebo 
(crossover) 
Week 8 
response 
100% ? NS overall Metronidazole 
1g daily 
improved 
symptoms 
and lab 
values in all 
six with 
colonic 
disease 
Sutherland154 12  
(4 received 
10 mg/kg; 
4 received 
20mg/kg;  
placebo) 
Placebo Week 16 
response 
Mean CDAI drop 
145, 95% CI 26-
265, n=8 
CDAI 
increased by 
mean of 61, 
n=4 
0.05 Metronidazole 
more effective 
than placebo 
in colonic and 
ileocolonic 
disease but 
not small 
bowel disease 
 
(b) Controlled trials of oral metronidazole  
 
 
Table 7. Trials of antibiotics where data provided separately for patients with isolated 
colonic Crohn’s disease. 
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Author/Ref N 
(isolated 
colonic 
CD) 
Budesonide/ 
Comparator 
Primary 
end point 
Budesonide 
remission 
rate  
Comparator 
remission 
rate 
P 
value 
Steroid related 
adverse events 
Conclusions 
Tromm157 50 (distal 
colon 
excluding 
rectum) 
of 307 in 
trial 
Budesonide 
9mg od vs 
3mg tds vs  
Mesalamine 
1.5g tds 
Week 8 
remission, 
CDAI≤150 
23/30 
(76.7%)  
10/20 
(50%)  
0.051 Only 1 budesonide 
patient with acne, 
no other steroid-
related events 
Budesonide 
borderline signif 
better than 
mesalamine 
Bar-Meir158 27 of 201 
in trial 
Budesonide 
9mg od vs  
Prednisone 
40mg od 
2wks then 
taper 
Week 8 
remission, 
CDAI≤150 
2/10 (20%) 10/17 
(58.8%)  
0.1 67% Prednisone vs 
44% Budesonide  
Trend towards 
better efficacy in 
colonic disease 
with Prednisone, 
similar efficacy if 
small bowel 
involved.  
(a) Controlled trials of pH-modified release oral Budesonide  
 
 
Author/Ref N 
(isolated 
colonic 
CD) 
Prednisone/Comparator Primary 
end point 
Prednis(ol)on
e remission 
rate  
Comparator 
remission rate 
P value Conclusion
s 
Summers146 34 of 295 
in trial 
(Pt1) 
Prednisone up to 60mg 
/day (n=8) vs 
Azathioprine 2.5 mg/kg 
(n=9) vs 
Sulfasalazine 1g/15kg 
(n=8) vs 
Placebo (n=9) 
Week 17 
remission 
Data 
presented as 
rank outcome 
Data 
presented as 
rank outcome 
0.465 Prednisone 
not effective 
in colon 
only 
disease 
(but only 
n=8 treated) 
Malchow147 49 of 215 
in trial 
(inductio
n data 
from 
table 11) 
Sulfasalazine or 
combination of 
sulfasalazine and 6-
methyl Prednisolone 
Remissio
n by week 
18 
6/8 (75%) Placebo 2/14 
(14%) 
Sulphasalazin
e 4/13 (31%) 
Combination 
13/14 (93%) 
<0.01 for 
Sulfasalazine and 
6-
methylprednisolon
e and <0.001 for 
combination 
All active 
treatments 
better than 
placebo but 
combination 
superior to 
either agent 
alone 
 
 
(b) Controlled trials of oral Prednis(ol)one  
 
Table 8. Trials of oral corticosteroids where data provided separately for isolated colonic 
Crohn’s disease. 
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Author Year Type of 
study 
Study agent Total 
number of 
patients 
Number 
with 
colonic 
CD 
Endpoint Main findings P value 
(for 
colonic vs 
other sites 
unless 
stated) 
Conclusion 
Sandborn165 2011 RCT Certolizumab 
pegol (CZP) 
338 120 Week 6 
remission 
(CDAI 
</=150) 
23/63 (36.5%) 
CZP vs 10/57 
(17.5%) 
placebo  
0.052 
(colon vs 
other 
locations);  
0.034* 
(active vs 
placebo)  
Probable 
efficacy in 
colonic 
disease 
Arnott166 2003 Cohort Infliximab 74 26 Week 4 
response 
(fall in HBI 
by >3) 
23/26 (88%) 
response in 
colonic vs 6/11 
(54%) in ileal 
0.042 Better 
efficacy in 
colonic than 
ileal 
Laharie167 2005 Cohort Infliximab 44 18 Week 8 
response 
(fall in CDAI 
by >/= 100) 
83.3% colonic 
CD vs 50% 
ileal/ileocolonic 
0.03 Better 
efficacy in 
colonic than 
combined 
ileal/ileocolo
nic 
Vermeire168 2002 Cohort Infliximab 240 89 Week 4 
(luminal) or 
week 10 
(fistulising) 
response 
(fall in CDAI 
by >/=70 or 
50% 
decrease in 
draining 
fistulae 
81% response 
colonic CD vs 
55% ileal CD 
vs 74% 
ileocolonic 
OR 1.905, 95% 
CI 1.010 – 
3.597 
0.046 Better 
efficacy in 
colonic than 
combined 
ileal/ileocolo
nic. 
Remission 
also more 
likely in 
isolated 
colonic 
(P=0.019) 
Dupont-
Lucas169 
2016 Cohort 
 
Infliximab 248 
(children) 
63 Loss of 
response to 
maintenance 
therapy 
(moderate or 
severe 
global 
assessment 
requiring 
cessation of 
therapy) 
Colonic 25/54 
(46%) 
responders or 
remitters vs 
ileal/ileocolonic  
148/185 (80%). 
iHR 2.72 (95% 
CI 1.30-5.71) 
for loss of 
response in 
isolated colonic 
CD vs other 
sites 
0.008 Isolated 
colonic 
disease 
more likely to 
lose 
response 
Cohen170 2012 Cohort Adalimumab 75 15 Time to dose 
escalation 
13.2 weeks for 
colonic vs 34.6 
weeks for other 
sites 
0.0062 Isolated 
colonic 
disease 
required 
earlier dose 
escalation 
Sandborn 171 2013 RCT Vedolizumab 1115 316 (273 
active, 43 
placebo) 
Subgroup 
analysis 
based on 
62 active 
and 43 
placebo. 
Remission 
(CDAI 
</=150) at 
week 6 over 
placebo, 
Response 
(CDAI fall 
>/=100) 
week 6 
Remission 
difference from 
placebo: 5.9% 
for colonic vs 
6.7% for ileal 
vs 8.9% for 
ileocolonic 
Response: 
10.6% for 
colonic vs 
minus 10.4% 
for ileal vs 
7.1% for 
ileocolonic 
0.30 
remission 
 
 
 
 
 
0.23 
response 
No 
difference 
between 
isolated 
colonic and 
other 
Crohn’s for 
induction 
with 
vedolizumab 
Sandborn171  2013 RCT Vedolizumab 461 117 Remission at 
week 52 
over placebo 
Remission 
8wkly vedo: 
18.9% 
difference from 
placebo for 
colonic vs 
11.8% for ileal 
0.11 
 
 
 
 
 
0.19 
No 
difference 
between 
isolated 
colonic and 
other 
Crohn’s for 
Page 35 of 80
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 36
vs 19.9% for 
ileocolonic 
Remission 
4wkly vedo: 
12.7% for 
colonic vs 
25.4% for ileal 
vs 12% for 
ileocolonic 
maintenance
with 
vedolizumab 
Table 9: Randomized controlled trials (RCTs) and cohort studies of biological therapy in 
Crohn’s disease where data were provided separately for patients with isolated colonic 
disease.  
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Author/ref Year Nature 
of 
study 
Adults/ 
children 
n= Intervention Duration Primary 
endpoint 
Results in 
patients 
with ileal 
involvement 
Results in 
isolated 
colonic CD 
P* 
Lochs177 1991 RCT Adults 55 (enteral 
nutrition; 9 
colon only); 
52 drug 
treatment 
Exclusive 
Peptisorb 
(oligopeptid
e diet) 
4-6 
weeks 
Remission 
(CDAI 
reduced by 
40% or 100 
points) 
 
Mean time 
till 
remission 
26 days 
Mean time 
till 
remission 
31 days 
NS 
Wilschanski178 1996 Retros
pective 
cohort 
Children 
7-17 
 
65 (5 colon 
only) 
Exclusive 
Amino-acid 
or peptide 
4weeks 
or more 
Remission 
PCDAI 
</=20 
Remission 
47/60  
(78%) 
Remission  
1/5 (20%) 
0.02 
Afzal179 2005 Prospe
ctive 
cohort 
Children 
8-17 
65 
(14 colon 
only) 
Exclusive 
polymeric 
8weeks Remission 
PCDAI<20 
Remission 
43/51 
(84%) 
Remission  
7/14 (50%) 
0.01 
Buchanan180 2009 Prospe
ctive 
cohort 
Children 
Median 
age 12 
110 (19 
colon only) 
Exclusive 
polymeric 
(Modulen) 
in 105, 
elemental 
in 5 
8 weeks Remission 
(improvt in 
all domains 
of global 
assesst)  
Remission 
73/91 
(80.2%) 
Remission 
15/19 
(78.9%) 
NS 
Rubio181 2011 Retros
pective 
cohort 
Children  
Mean age 
11 
106 (26 
colon only) 
Exclusive 
polymeric 
(Modulen) 
8 weeks Remission 
PCDAI<10 
Remission 86/106  (81%) 
overall, colonic data not 
presented separately but 
site not correlated with 
outcome 
NS 
De Bie182 2013 Retros
pective 
cohort 
Children  
Median 
age 14 
76 (18 
colon only) 
Exclusive 
polymeric 
or semi-
polymeric 
6 weeks Remission 
defined as 
no diarrhea, 
pain or wt 
loss 
Remission 
32/51 
(63%) 
Remission 
8/15 (53%) 
NS 
 
 
Table 10. Results of exclusive enteral nutrition as primary therapy in Crohn’s disease where data 
provided separately for isolated colonic Crohn’s disease. 
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 Ileal/Ileocolonic 
Crohn’s disease 
Isolated colonic 
Crohn’s disease 
Ulcerative colitis 
Sex Slightly commoner in 
females (c55%)  
Commoner in females 
(c65%) 
Equal or slight male 
predominance  
Genetics Crohn’s-associated  
genotype including 
NOD2/CARD15 
Genotype midway 
between Crohn’s and 
UC 
Associated with HLA-
DRB1*01:03 but not 
NOD2/CARD15  
UC-associated 
genotype including 
HLA-DRB1*01:03 
Smoking Marked association  
Worsens prognosis 
Weak association  
Possibly worsens 
prognosis 
Marked negative 
association  
Oral contraception Positively associated Positively associated Positively associated 
(mainly in smokers) 
Serology ASCA commonly 
positive 
pANCA usually 
negative 
ASCA less commonly 
positive than 
ileal/ileolonic CD 
pANCA positive in 
minority 
ASCA usually negative 
pANCA commonly 
positive 
Mucosa-associated 
Microbiota 
Marked changes 
commonly including 
increased 
Proteobacteria (eg E. 
coli) and Fusobacteria, 
reduced Firmicutes (eg 
F. prausnitzii 
Intermediate changes 
similar to ileal/ileo-
colonic CD but less 
consistent 
Modest changes, 
including slight 
increase in E. coli but 
no reduction in F. 
prausnitzii 
Response to 
mesalazine 
No efficacy No efficacy Good efficacy 
Response to anti-TNF Good efficacy Good efficacy – 
probably better than 
for ileal/ileocolonic 
 
Good efficacy 
Response to excusive 
enteral nutrition 
Good efficacy Probably good efficacy 
but mixed reports 
No efficacy 
Surgery rate and 
type 
Required in majority Required in minority 
Segmental colectomy 
effective 
High failure for pouch-
anal reconstruction  
Required in minority 
Segmental colectomy 
not effective 
Low failure for pouch-
anal reconstruction 
 
 
 
Table 11. A summary of the distinguishing features of the three inflammatory bowel 
diseases: ileal/ileocolonic Crohn’s disease, isolated colonic Crohn’s disease, ulcerative colitis. 
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Comparison between Crohn’s disease genetic risk score and ulcerative colitis genetic risk score for different 
locations of Crohn’s disease, ulcerative colitis and IBD unclassified (from Cleynen et al,17 with permission. 
This shows that isolated colonic Crohn’s lies approximately equidistant genetically between ileal Crohn’s 
disease and ulcerative colitis.  
Crohn’s disease similarly ov  
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Isolated colonic Crohn’s as percentage of all Crohn’s disease by year in studies reporting sequential data 
from the same centres or geographical areas.  
total Crohn’s from 1970 to 1  
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Isolated colonic Crohn’s disease as percentage of all Crohn’s disease by year in all studies.  
(p=0.02 by polynomial regressi  
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Recent advances in clinical practice: a systematic review of isolated colonic Crohn’s 
disease – the third inflammatory bowel disease?  
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ABSTRACT 
The genetics of isolated colonic Crohn’s disease place it approximately midway between 
Crohn’s disease with small intestinal involvement and ulcerative colitis, making a case for 
considering it as a separate condition. We have therefore systematically reviewed its 
epidemiology, pathophysiology, and treatment.  Key findings include a higher incidence in 
females (65%) and older average age at presentation than Crohn’s disease at other sites, a 
mucosa-associated microbiota between that found in ileal Crohn’s disease and ulcerative 
colitis, no response to mesalazine, but possibly better response to anti-TNF than Crohn’s 
disease at other sites. Diagnostic distinction from ulcerative colitis is often difficult and also 
needs to exclude other conditions including ischaemic colitis, segmental colitis associated 
with diverticular disease and tuberculosis. Future studies, particularly clinical trials, but also 
historical cohorts, should assess isolated colonic Crohn’s disease separately. 
 
INTRODUCTION 
 
Diagnosis of Crohn’s disease is often contentious when ileal involvement is lacking. This has 
a long history. Colitis with skip lesions and rectal sparing was considered in 19301 as 
“regional migratory ulcerative colitis”. Crohn’s classic 1932 paper did not include cases with 
colonic involvement2 although non-tuberculous granulomatous involvement of ileum and 
colon had been reported in 19233 and later by others.4, 5 From the 1930’s to the 1950’s, 
colitis without rectal or terminal ileal involvement was usually designated “regional” or 
“segmental” colitis.6  
 
The British surgeon Wells first used “Crohn’s disease of the colon” when describing cases of 
granulomatous regional colitis in 1952.7 Initially this was not widely accepted and Kirsner 
(1960) continued to refer to cases with submucosal granulomata and skip lesions as 
ulcerative colitis.8 Identification of Crohn’s disease of the colon separately from ulcerative 
colitis was strongly reinforced by Lockhart-Mummery and Morson, (1960) who described 25 
cases with features including non-bloody diarrhoea, anal fistulae, rectal sparing, skip lesions 
and strictures.9 Histopathology showed submucosal giant cell granulomata, fibrous 
thickening, and regional lymph node enlargement. This paper caused a “paradigm shift” that 
has led practice since. It was reinforced the following year when Cornes and Stecher 
reported 45 patients with isolated colonic Crohn’s disease, with fistulation in nearly two 
thirds, and skip lesions in 20% .10  
 
Later evidence that colonic Crohn’s disease, unlike ulcerative colitis, might be improved by 
faecal diversion,11, 12 treatable by segmental resection13, and associated with poor outcomes 
after ileal pouch-anal anastomosis,14 seemed to confirm even more securely its position as a 
form of Crohn’s disease and distinct from ulcerative colitis.  
 
Distinction of colonic Crohn’s disease from ulcerative colitis may be difficult though. The 
term “indeterminate colitis” was introduced to describe cases, “10-20%”, where, after 
colectomy and examination of the resected colon, a clear diagnosis is not possible.15 The 
term was often incorrectly applied to patients without colectomy until “inflammatory bowel 
disease unclassified” (IBD-U) was recommended for such cases.16 
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The scene is now changing again – extensive data show that isolated colonic Crohn’s disease 
is genetically separable from Crohn’s disease involving the small intestine.17 When the ratio 
of Crohn’s-associated genes to ulcerative colitis-associated is compared with disease 
phenotype isolated colonic Crohn’s disease lies approximately midway between ileal 
Crohn’s and ulcerative colitis. IBD-U, although statistically separable from ulcerative colitis 
overlaps it considerably and ileo-colonic Crohn’s disease similarly overlaps ileal Crohn’s 
disease (Figure 1). This finding led to recommendation that Crohn’s disease with ileal 
involvement (ileal and ileocolonic), isolated colonic Crohn’s disease and ulcerative colitis 
should be considered as three separate conditions.  
 
It is therefore timely to review the epidemiology, genetics, serology, microbiology, and 
response to treatment of isolated colonic Crohn’s disease and to reconsider whether this 
“evidence” favours isolated colonic Crohn’s disease as a variant of Crohn’s disease, as a 
variant of ulcerative colitis, or as a separate condition.  
 
METHODS 
The medical literature was searched using National Library of Medicine/Pubmed to 1st 
December 2015 using the terms “colonic and Crohn’s” “Crohn’s and colitis” “epidemiology 
and Crohn’s”. We conducted additional searches for “smoking and Crohn’s disease” and 
“oral contraception and Crohn’s”. Later (to 1st June 2016) additional searches for “Crohn’s” 
and each of the therapies covered were performed. After removal of duplicates and 
screening of abstracts for relevance, 840 were selected for further review (Supplementary 
Figures 1 &2). Whilst the literature search was fully systematic, the subject of this review is 
necessarily much broader than that of a conventional systematic review. We have only 
included full publications in english language and have not attempted to judge quality of the 
data. For epidemiological studies we included all reports that (a) contained data on at least 
100 patients with Crohn’s disease and (b) included separate data for isolated colonic 
Crohn’s disease (Montreal classification L2). Where published studies had overlapping 
patient base and time period we used only the more completely described data set to avoid 
duplication. For other aspects of the review (genetics, serological testing, response to 
therapies and association with environmental factors) we included all studies that identified 
isolated colonic Crohn’s disease separately. For therapeutic studies we have separately 
identified data that have been obtained from randomized clinical trials and those that have 
been obtained from cohort studies. It should be noted that, whereas pure ileal Crohn’s and 
pure colonic Crohn’s should be readily distinguished by a comprehensive diagnostic 
assessment including ileal intubation, incomplete assessment could mislabel ileocolonic as 
colonic. This should be taken into account particularly in respect of older studies but we 
have taken care to ensure that all data included here regarding isolated colonic disease 
relate to patients thought at the time of publication not to have ileal disease. Statistical 
analysis was performed using StatsDirect3 v 3.0.171 StatsDirect Ltd, UK. 
 
PATHOLOGY, DIFFERENTIAL DIAGNOSIS, AND DISEASE COURSE – DEFINING THE 
CONDITION 
The histological features of isolated colonic Crohn’s disease were first defined by Lockhart-
Mummery and Morson.9 They labeled patients with this diagnosis because “they had the 
same characteristic pathology in the large intestinal lesions as that described by Hadfield18 
for the disease as it affects the small intestine”. Gross appearances of the colon following 
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colectomy include less sharp demarcation of ulceration than typically seen in ulcerative 
colitis and with areas of intact intervening mucosa. In some cases, very marked fibrous 
thickening with associated stricturing was present. Fibrosis and oedema sometimes 
extended into the pericolic fat and enlargement of regional lymph nodes was marked. 
Warren later split the macroscopic features into three patterns: isolated rectal disease; 
stricturing colonic disease; diffuse colitis – usually with rectal sparing, and noted that 
approximately 75% develop perianal pathology during their disease course.19 
 
Microscopic features described by Morson included discontinuous inflammation and 
ulceration which could extend into the submucosa or deeper into the wall as the basis of 
fistula formation, plus focal crypt irregularity. Non-caseating epithelioid granulomas were 
present in the majority, distributed through all layers of the bowel wall as well as regional 
lymph nodes. Other features included submucosal lymphangiectasia and neuromatous 
hyperplasia.20 It has subsequently been noted that the earliest lesions – aphthous ulcers – 
which usually overlie lymphoid follicles, are preceded by a “red ring” sign on colonoscopy, 
biopsy of which reveals a lymphoid follicle surrounded by reactive hypervascularisation.21 
 
Histopathology alone is diagnostic only in the minority – in a series of 103 cases of Crohn’s 
colitis, diagnosis was determined by microscopy alone in 28%, by distribution (rectal sparing 
and/or discontinuity) alone in 22% and by combination of the two in 50%.22 Particularly 
discriminatory features suggesting Crohn’s colitis rather than ulcerative colitis include 
granulomata, submucosal inflammation, and relative preservation of goblet cells.23,24 At an 
international workshop expert pathologists “correctly” identified only 64% of cases with 
Crohn’s colitis and 74% with ulcerative colitis25 leading the European consensus on 
histopathology of inflammatory bowel disease (2013) to note that “accurate discrimination 
between the two diseases (Crohn’s colitis and ulcerative colitis) is not yet optimal amongst 
expert gastrointestinal pathologists”. Given that inflammatory disease pathogenesis is 
multifactorial an alternative interpretation would be that there is a continuous phenotypic 
spectrum that runs through from “typical” ulcerative colitis, through IBD-unclassified to 
“typical” Crohn’s colitis.  
 
Early studies reported an additional incidence peak of Crohn’s disease in the elderly 
resulting from cases particularly affecting the sigmoid colon.26 Following the later 
clarification of segmental colitis associated with diverticular disease (SCAD) this seems 
probably attributable to SCAD. SCAD can be indistinguishable histologically from 
inflammatory bowel disease and includes a “Crohn’s-like” variant with granulomata.27 This 
reflects emphasis often placed on the diagnostic specificity of the granuloma. However, 
granulomas are only found in colonoscopic biopsies at diagnosis in about 66% of adults with 
colonic Crohn’s disease, falling to 18% at follow-up.28 Moreover granulomas, particularly in 
association with crypts, can be found in ulcerative colitis.29 Other forms of colitis that may 
need to be considered in the differential include ischemic colitis (see earlier) and infections 
including amoebiasis and tuberculosis but it is beyond the scope of this review to consider 
these further. 
 
Localisation of disease to the colon remains fairly constant over time. The largest published 
data set by far is the 16,902 Crohn’s disease cohort, including 2,933 with isolated colonic 
disease, in the recent genotype/phenotype association study.17 This confirmed previous 
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 5
reports of low rates of progression to ileo-colonic disease (5-14% over 7-10 years). 30-32 
Although luminal narrowing is common, stricturing (B2 disease) as defined in the 
Vienna/Montreal classifications requires the presence of prestenotic dilatation or 
obstructive signs or symptoms and this very rarely occurs, eg 0/45 cases in a Belgian series 
33 whereas penetrating disease (B3) as defined by the Vienna classification (ie including peri-
anal fistulae) occurred in 23% in the same series, less frequently than in patients with ileal 
disease (46%; P=0.0003) or ileocolonic (28.6%; NS). The much larger genotype/phenotype 
association study confirmed that cumulative probability of progression to B2 and B3 
combined over ten years was substantially lower in colonic disease – 23%, than in 
ileocolonic disease - 62%, or ileal disease - 68%.17 The risk of surgery (discussed later) was 
also much lower at ten years (22%) than for ileo-colonic (42%) or ileal disease (62%). A 
recent meta-analysis showed that colon cancer risk in isolated colonic Crohn’s disease is 
similar to ulcerative colitis of equivalent extent with a pooled standardized incidence ratio 
(SIR) of 1.7; 0.9-2.6 95%CI (population based data) compared with SIR 1.8; 1.2-2.4 for 
ulcerative colitis but rising to SIR 18.2; 7.8-35.8 for extensive colonic Crohn’s disease in a 
referral centre population compared with SIR 21.6; 15.0-31.0 for extensive ulcerative 
colitis.34 
 
EPIDEMIOLOGY 
Changes over time 
Studies reporting sequential data from a single centre or region show interesting time 
trends. Studies from UK35,36 and Sweden37 reported a marked increase in isolated colonic 
Crohn’s as a proportion of total Crohn’s from 1970 to 1990 (Figure 2A) whereas later 
studies, particularly from France38 have shown a downward trend since 1990. When looked 
at across all geographical areas, (Table 1), although there is no obvious difference in 
proportion of isolated colonic disease between countries or regions, there is a similar time 
trend with increase in isolated colonic disease between 1960 and 1990, peaking at an 
average of about one third of all Crohn’s disease cases, and decreasing since (p=0.02 by 
polynomial regression, Figure 2B).  
 
Sex variation 
We found eight studies which stated the sex distribution of patients with isolated colonic 
Crohn’s disease. In all but one the female preponderance was equal or greater to that 
reported from the same study for total Crohn’s disease (Table 1) – isolated colonic Crohn’s 
disease averaging 65.1% female, compared with Crohn’s disease excluding isolated colonic 
55.3% female (P=0.027 by paired t test). 
 
Age at diagnosis 
Age at diagnosis of isolated colonic Crohn’s disease (in seven studies; Table 1), has a median 
between 28 and 45, around 10 years older than generally reported for all Crohn’s – eg 
median 25 years in the 16,902 patients studied by Cleynen et al17. Older age of isolated 
colonic versus other sites of Crohn’s disease was also confirmed by the IBDchip European 
Project.85 The preponderance of isolated colonic disease amongst children with very early 
onset Crohn’s disease is discussed later. 
 
Smoking 
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 6
Cigarette smoking is associated with increased risk for development and progression of 
Crohn’s disease but reduced risk for ulcerative colitis. Smoking is more strongly associated 
with risk for ileal and ileo-colonic Crohn’s disease than for isolated colonic disease (Table 2). 
Only one study (of nine)79 reported a higher rate of smoking amongst patients with isolated 
colonic Crohn’s disease. If the South African data84 which reported exceptionally high rates 
(73%) across all groups are excluded, the other studies report rates for smoking amongst 
patients with isolated colonic disease that averaged 37.8% compared with 49.8% (P=0.008 
by paired t test) for other Crohn’s disease sites. This smoking rate is probably slightly higher 
than for the general population – approximately 30% European adults were smokers in 2008 
(WHO).86 
 
Smoking worsens prognosis of Crohn’s disease overall and cessation of smoking improves 
it.87,88 This has been studied less in isolated colonic disease but the conclusion is similar. The 
largest study80 included 688 patients with Crohn’s colitis, 978 with ulcerative colitis and 118 
with “indeterminate” colitis. Sixty-one per cent of patients with ulcerative colitis or 
indeterminate colitis had stopped smoking before disease onset compared with only 12% in 
isolated colonic Crohn’s disease. In women but not men with isolated colonic disease the 
risk of needing immunosuppression was increased amongst smokers (10-yr cumulative risk 
48% in non-smokers vs 58% in smokers, P<0.01). An earlier study74 showed that smokers 
with Crohn’s colitis relapsed approximately 50% more often (P=0.028) and with more pain 
(P<0.007) than non-smokers.  
 
Thus smoking at best has a neutral effect on isolated colonic Crohn’s disease but more likely 
is harmful. 
 
 
Oral contraception 
Meta-analysis of 14 studies, with adjustment for smoking, showed a relative risk of 1.51 
(95%CI 1.17-1.96, P=0.002) for Crohn’s disease amongst women currently taking oral 
contraception89. The relative risk for ulcerative colitis was also increased at 1.53 (1.21-1.94, 
P=0.001). Six of the seven studies that reported risk associated with oral contraception 
separately for isolated colonic disease found a significant association (Table 3) with 
relatively high odds ratio (2.63), risk ratios (3.6 and 3.23) or hazard ratio (4.13). The sole 
exception91 only included 8 cases with isolated colonic Crohn’s disease and showed no 
overall association between oral contraception and risk for Crohn’s disease. Excluding the 
latter study91, five of the other six show higher risks amongst oral contraceptive users for 
isolated colonic Crohn’s than for other sites. 
 
Oestrogen-associated ischaemic colitis as a confounder 
 
An early study from Birmingham50 reported patients with apparent oral contraceptive-
associated colonic Crohn’s disease who had non-granulomatous colitis with rectal sparing.  
Ischaemic colitis is a rare but recognized complication of oral contraception that might 
cause diagnostic confusion. 97,98,99 Most cases have a short duration with typical features of 
ischaemic colitis including abdominal pain, and rectal bleeding. Colonoscopy shows mucosal 
friability but no linear ulceration and the proximal colon and rectum are typically normal. 
Such cases should be readily distinguishable from colonic Crohn’s disease but Tedesco100 
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 7
reported five cases of oral contraceptive-associated colitis with features that overlapped 
more with colonic Crohn’s disease than ischaemic colitis. Moreover, colonic 
“thumbprinting”, a characteristic feature of ischaemic colitis, has been reported in Crohn’s 
disease.101 It is unclear whether diagnostic overlap with milder cases of oral contraceptive-
associated ischaemic colitis contributes to the female preponderance of isolated colonic 
Crohn’s disease. If it does then the change to lower oestrogen dosing in later versions of the 
contraceptive pill might be a plausible explanation for the apparent fall off in cases in recent 
decades.102 Clinicians should be aware of the possible associations between oral 
contraception and inflammatory bowel disease or ischaemic colitis and advise patients 
accordingly – such advice should usually include at least a temporary cessation of oral 
contraception to assess impact on the colitis. 
 
GENETICS 
The strongest genetic association with IBD is the link between NOD2/CARD15 and Crohn’s 
disease. Meta-analysis of 42 studies showed that this association was stronger for Crohn’s 
disease with small bowel involvement than for those without (OR 2.53; 95%CI 2.01-3.16).103 
Subsequent study of 1528 patients with Crohn’s disease from 8 centres (in 7 European 
countries) (IBDchip) confirmed the association of NOD2/CARD15 with ileal involvement and 
also showed that Interleukin23 receptor polymorphisms were more strongly associated with 
isolated colonic Crohn’s (OR 2.20; 95%CI 1.17-4.57).85  
 
The most consistent genetic link with ulcerative colitis is with the rare Major 
histocompatibility Complex (MHC) / Human Leucocyte Antigen (HLA) Class II allele HLA-
DRB*0103. This occurs in less than 2% in European and white North American populations 
and is absent in the Japanese. It is strongly associated with colonic Crohn’s disease where it 
is present at up to 32% frequency with Odds Ratios for isolated colonic disease of 5.1-18.5 
compared with Crohn’s disease at other sites.104 
 
The largest study to compare genetic associations with Crohn’s disease phenotype included 
19713 patients from 49 centres across 16 countries in Europe, North American and 
Australasia.17 This confirmed that the strongest association with isolated colonic Crohn’s 
disease was HLA-DRB1*01:03 (p=1.47 x 10-23, ileal vs colonic OR 0.32, 95%CI 0.29-0.41; 
ileocolonic vs colonic OR 0.47, 95%CI 0.39-0.57). The only other loci that were significant 
across all analyses in this study were NOD2 (16q12), again associated with increased risk for 
ileal involvement (OR ileocolonic vs colonic 1.61,1.59, and 1.89 for the three NOD2 
polymorphisms tested) and also MST1 (macrophage stimulating -1 that encodes a protein 
which induces macrophage phagocytosis) polymorphisms which were more weakly 
associated with ileal involvement (OR 1.07 -1.10 according to polymorphism and whether 
comparing ileal or ileocolonic with colonic disease). When overall genetic risk scores for 
Crohn’s disease and ulcerative colitis were computed as a ratio and compared with 
phenotype, isolated colonic Crohn’s disease was found to be approximately “balanced” in 
respect of Crohn’s disease versus ulcerative colitis genetic risk factors (Figure 1). It was 
found though that even the combination of smoking status with the strongest genetic 
predictors could only explain 6.8% of the variance for disease location.  
 
ISOLATED COLONIC CROHN’S DISEASE IN CHILDHOOD AND SINGLE GENE DISORDERS 
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 8
Amongst children with very early onset Crohn’s disease there is a marked preponderance of 
cases with isolated colonic disease eg 76.5% before age 5105 and 42% before age 8.106 
Amongst younger cases there is a strong male preponderance – eg 1.6:1 across all Crohn’s 
disease presenting <5105 and some of this is accounted for by X-linked single gene disorders. 
The first such condition to be identified was X-linked Chronic Granulomatous Disease.  
Chronic Granulomatous Disease is associated with defects in neutrophil function leading to 
skin lesions and in around 40% with a form of inflammatory bowel disease that is 
indistinguishable from Crohn’s disease, typically with predominant colorectal and perianal 
involvement .107 It is due to mutations in one of four NADPH oxidase complex component 
genes of which the commonest (CYBB) located on the X chromosome accounts for about 
65% cases.   
 
Rapid developments in DNA sequencing have allowed identification of over 50 further single 
gene disorders that present as inflammatory bowel disease, typically as colonic disease and 
with presentation before age 6, defined as Very Early Onset IBD or VEO-IBD.108 VEO-IBD 
cases account for 4-10% of paediatric inflammatory bowel disease.109 One of the commoner 
single gene variants is in the coding region of X-linked inhibitor of apoptosis protein (XIAP) 
that accounts for about 4% of male patients with paediatric onset Crohn’s disease.110 
 
 
SEROLOGY INCLUDING ANTI-MICROBIAL AND ANTI-NEUTROPHIL ANTIBODIES 
Anti-microbial antibodies such as Anti-Saccharomyces cerevesiae (ASCA) and antibodies to 
outer membrane protein (ompC) are found less often and/or at lower titre in isolated 
colonic Crohn’s than in other Crohn’s phen types.111 Meta-analyses confirm this particularly 
for ASCA.112-114 Average sensitivity of ASCA for isolated colonic Crohn’s disease diagnosis is 
31% but with a wide range (8-59%) and an average 14% positivity rate in ulcerative colitis 
(Table 4).  The clinical utility of ompC antibodies has been less studied but reported 
positivity/sensitivity in isolated colonic Crohn’s disease is substantially lower than that for 
ASCA. 
 
Anti-neutrophil antibodies, particularly an atypical peri-nuclear antibody (pANCA), are 
present in around 55% of patients with ulcerative colitis114 and 23% of patients with isolated 
colonic Crohn’s disease (Table 4). This compares with pANCA positivity of around 11% in 
Crohn’s disease overall and 3% in non-IBD controls.114 
 
A combination of positive ASCA and negative pANCA is more discriminatory eg positivity 
rate in isolated colonic Crohn’s disease of 52% compared with 9% in ulcerative colitis122 but 
is still insufficiently predictive for routine clinical use.125 
 
Thus the frequency in isolated colonic Crohn’s disease of both ASCA and pANCA antibodies 
lies somewhere in between that found in Crohn’s disease with ileal involvement (more likely 
ASCA+, and pANCA-) and that found in ulcerative colitis (more likely ASCA- and pANCA+).  
 
 
MICROBIOTA 
The faecal microbiota in active inflammatory bowel disease is commonly dysbiotic with 
reduced bacterial diversity.126,127 This could be secondary to inflammation yet still significant 
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 9
in maintaining chronicity. The large study of pre-treatment Crohn’s disease by Gevers 
showed only a mild dysbiosis in the faecal microbiota and much greater separation of 
Crohn’s disease from healthy controls when the mucosa-associated microbiota was 
studied.128 Ileal and rectal mucosal samples typically showed a reduction in Firmicutes such 
as Faecalibacterium prausnitzii and an increase in Proteobacteria such as Escherichia coli as 
well as in Veillonella, Haemophilus and Fusibacteria. This confirmed many previous studies 
sh wing an increase in mucosa-associated E. coli in Crohn’s disease as well as several 
showing a reduction in F. prausnitzii129-132.  
 
The faecal and mucosa-associated microbiota in isolated colonic Crohn’s disease are 
generally closer to that of healthy controls than is found in patients with ileal or ileocolonic 
Crohn’s disease (Table 5). Thus Baumgart et al129 found that an increase in ileal mucosa-
associated E. coli and reduction in ileal F. prausnitzii was only present in patients with 
Crohn’s disease who had ileal involvement and not in those with isolated colonic disease. 
Similarly, a study of twins with/without Crohn’s disease showed that faecal microbial 
diversity was only reduced and Proteobacteria increased in patients with ileal involvement 
and not in patients with isolated colonic disease.130 A previous report by the same group 
also showed a reduction in F. prausnitzii in Crohn’s patients with ileal involvement but not in 
isolated colonic disease.131 Both the twin study by Willing131 and the large study in 
children128 and adolescents134 did however show differences between the mucosa-
associated microbiota in isolated colonic Crohn’s disease and ulcerative colitis. 16sRNA 
pyrosequencing of mucosal samples133 confirms the increase in E. coli and reduced F. 
prausnitzii in Crohn’s disease with ileal involvement with milder changes in isolated colonic 
disease, although the latter did show some reduction in F. prausnitzii compared with 
healthy controls. This study also confirmed that the mucosa-associated microbiota are 
consistent at different sites from ileum to rectum in the same individual. 
 
In conclusion, mucosa–associated microbiota changes in Crohn’s disease are more marked 
than faecal changes. The microbiota in isolated colonic Crohn’s disease, show changes that 
tend to be less marked and less consistent than those found in Crohn’s disease with ileal 
involvement. 
  
 
 
RESPONSE TO TREATMENT 
 
Mesalazine 
 
Systematic reviews show no convincing benefit of oral mesalazine (5-aminosalicyclic acid) 
over placebo either in induction of remission or in maintenance of medically induced 
remission in Crohn’s disease as a whole1345138 although they may have a modest benefit in 
maintaining surgically-induced remission.139 Sulphasalazine (sulphapyridine linked via azo 
bond to 5-aminosalicylate) has possible modest efficacy in induction of remission.134, 136 
 
Amongst trials that have reported data separately for isolated colonic Crohn’s disease, only 
one trial studied the effect of oral mesalazine in remission induction140 and four studied its 
effect in maintenance of medically-induced remission141-144 (Table 6). In none of these was 
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 10
mesalazine significantly more effective than placebo but in two studies141,142 there was a 
weak signal suggesting a better response in ileal disease. A single trial of olsalazine showed 
worse results than for placebo, probably because of drug-related diarrhea.145 Sulphasalazine 
was no better than placebo in two trials of maintenance146,147 but there was a weak signal of 
efficacy in remission induction in two trials147,148 but these only studied 17 and 27 patients 
with isolated colonic disease respectively (including placebo). Apart from case reports there 
have been no published studies of rectal mesalazine in isolated colonic Crohn’s disease. 
 
It can be reasonably concluded that mesalazine and olsalazine do not have efficacy in 
isolated colonic Crohn’s disease. Sulphasalazine possibly has some efficacy in remission 
induction. 
 
Antibiotics 
 
Systematic reviews suggest a beneficial effect for antibiotics in the induction of remission 
for Crohn’s disease though these have included diverse antibiotics and small trials.149-151 The 
largest study to date is for rifaximin.152 Three doses were tested: 400, 800, 1200mg or 
placebo twice daily for 12 weeks with good efficacy overall but no dose response. Amongst 
patients with isolated colonic disease higher remission rates (51%) were found for rifaximin 
(pooled doses) than for placebo (37%) and efficacy was better in this group than for other 
disease sites (Table 7). 
 
Metronidazole has also shown better efficacy in isolated colonic Crohn’s disease but based 
on very small numbers (Blichfeldt153: n=6 crossover; Sutherland154: 8 active and 4 placebo). 
In a study of 134 patients randomly assigned to ciprofloxacin and metronidazole, both 
500mg twice daily, or placebo in combination with budesonide 9mg daily155 a trend was 
seen towards benefit in patients with colonic involvement compared with those without but 
separate data were not reported for patients with isolated colonic disease. A large 
randomized trial of long duration (up to 2 years) antibiotic therapy (clarithromycin, rifabutin 
and clofazimine) targeted against Mycobacterium avium paratuberculosis in patients also 
receiving tapered prednisolone showed short term efficacy with 66% active in remission at 
16 weeks compared with 50% placebo  (P=0.02) and 39% relapsed by 12 months compared 
with 56% placebo (P=0.054).156 No differential response was seen according to disease 
location but data were not presented separately for patients with isolated colonic disease. 
Rifaximin and metronidazole thus show some evidence of efficacy in patient with isolated 
colonic Crohn’s disease and antibiotics tend to perform better in this group of patients than 
in Crohn’s disease at other sites but based on very small data sets. Further trials are clearly 
needed. 
 
Corticosteroids 
 
Given the widespread use of corticosteroids in Crohn’s disease the quality of evidence for 
their efficacy is surprisingly poor. There have only been two placebo-controlled trials of 
standard glucocorticosteroids.147,148 Each of these included only 8 steroid-treated patients 
with isolated colonic disease (Table 8) with one trial147showing no benefit and the 
other148showing efficacy. There has never been a trial to assess dose-responsiveness to 
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 11
conventional corticosteroids in Crohn’s disease so optimal dosage is unknown. More data 
are available for budesonide but trials have focused predominantly on patients with ileal or 
ileo-colonic disease so data in isolated colonic disease are again very sparse. The data from 
one comparison with mesalazine157, support efficacy in isolated colonic Crohn’s disease, 
possibly with a weaker effect than conventional corticosteroids158, but reduced 
corticosteroid side-effects. 
 
 
 
Anti-TNF 
 
None of the randomised trials of infliximab159,160 or adalimumab161-164 reported subgroup 
analyses of outcomes based on disease location. In a randomised, placebo controlled trial of 
certolizumab pegol, patients with colonic (OR 2.39, 95% CI 0.99-5.75, P=0.052) and 
ileocolonic disease (OR 2.07, 95% CI 1.01-4.28, P=0.048) were more likely to achieve 
remission at week 6 compared to ileal disease (OR 0.42, 95% CI=0.18-0.99, P=0.048)165(Table 
9) 
 
Several cohort studies have assessed colonic disease location as a predictor of response to 
anti-TNF agents, four with infliximab and one with adalimumab. Three cohort studies 
assessing induction therapy with infliximab166-168 all showed better response rates in 
isolated colonic disease than for disease at other sites. Paradoxically, cohort studies of 
infliximab maintenance in children169 and of adalimumab maintenance in adults170 both 
showed higher risk of lost response or dose escalation in isolated colonic disease. Overall, 
the evidence supports good efficacy for anti-TNF therapy in induction of remission in 
isolated colonic Crohn’s disease but possibly with a higher subsequent rate of loss of 
response. 
Vedolizumab 
In the combined induction and maintenance study of vedolizumab there was no significant 
difference in efficacy in isolated colonic disease compared with other locations.171 (Table 9) 
Enteral nutrition 
Exclusive enteral nutrition is effective as primary therapy in patients with active Crohn’s 
disease172,173 and partial enteral nutrition has shown efficacy in maintenance of remission.174 
In ulcerative colitis total parenteral nutrition and bowel rest are ineffective175 and 
comparison of enteral with parenteral nutrition showed no difference in efficacy176 implying 
no efficacy for enteral nutrition either.  Whether enteral nutrition is effective as primary 
therapy in isolated colonic Crohn’s disease is controversial. Relatively few studies provide 
separate data on patients with isolated colonic Crohn’s disease (Table 10). Five of the six 
studies are in children. Two studies178,179 report poorer results in children with isolated 
colonic disease compared with those with small intestinal involvement. Numbers are small 
though (19 cases of isolated colonic disease across the two trials) and the other studies 
(including 72 cases of isolated colonic disease across four trials) found no significant 
difference in remission rates for those with isolated colonic disease compared with other 
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 12
sites. Further trials of exclusive enteral nutrition are needed in patients with isolated colonic 
disease. 
 
Surgery 
Faecal diversion 
Colonic Crohn’s disease commonly responds to “bowel rest” induced by a defunctioning 
ile stomy whereas ulcerative colitis does not.11, 12 Instillation of unfiltered ileostomy 
contents into the defunctioned colon induced relapse whereas instillation of content that 
had passed through a 0.22micron pore diameter filter did not, implying a role for bacteria in 
pathogenesis.183 Defunctioning ileostomy has become less commonly performed for the 
treatment of uncomplicated colonic Crohn’s disease since it was shown that at least 50% 
relapsed after continuity was restored.184 
 
Resection 
The cumulative risk of surgery for isolated colonic Crohn’s disease is reported as 22-33% by 
10 years after diagnosis compared with around 75-90% for ileal disease.17,67 Partial 
resection, either right hemicolectomy for proximal disease or a segmental resection for 
more distal disease has been shown to be successful therapy for colonic Crohn’s disease185, 
186 as is colectomy with ileo-rectal anastomosis for more extensive disease if the rectum is 
uninvolved187,188. Approximately 75% of patients with ileo-rectal anastomosis will still have a 
functioning anastomosis after 10 years and about two thirds of those treated by segmental 
resection will not have required a further resection.188 Recurrence rates are similar after 
either procedure.189 This contrasts with left-sided ulcerative colitis, where the tempting 
option of left hemicolectomy with right-sided colo-anal anastomosis consistently fails, 
usually with rapid recurrence of colitis in the retained colon.190 It should be noted though 
that segmental resection for colon cancer complicating colonic Crohn’s disease has been 
associated with high (39%) risk for metachronous colon cancer191 suggesting that 
panproctocolectomy might be a safer option for such patients.  
 
Ileo-anal pouch reconstruction 
Crohn’s disease has generally been considered a contra-indication for restorative ileo-anal 
pouch surgery and even in selected patients pouch failure of 57% has been reported from 
the UK.192 Others have suggested that it may be successful in very carefully selected 
patients. Thus, a series of 3,707 patients with ileal-pouch anal anastomosis from the 
Cleveland Clinic included 150 with Crohn’s disease, of whom 32 had a pre-operative 
diagnosis, the remainder diagnosed by post-operative histopathology or on follow-up. 
Amongst 59 patients with Crohn’s disease reaching 10 year follow-up, pouch survival was 
80%.193 Forty nine of 132 patients (37%) needing pouch excision had a histological diagnosis 
of Crohn’s disease. Considering that a pre-operative diagnosis of Crohn’s disease was only 
present in less than 1% of patients receiving pouch-anal anastomosis these data do not 
make a strong case for this procedure in patients with a definite diagnosis of colonic Crohn’s 
disease.  
 
 
CONCLUSION  
Current data suggest that the genetics, microbiota, serology and smoking association of 
isolated colonic Crohn’s disease lie between those of ileo/ileocolonic Crohn’s disease and 
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ulcerative colitis and make a strong case for this phenotype being considered separately 
(Table 11). Genetic data in particular show good separation from ileal/ileocolonic Crohn’s 
disease and the low rate of progression from isolated colonic to ileo-colonic disease help to 
justify this distinction. There is a disappointing paucity of good quality therapeutic data but 
the lack of response to mesalazine, whose target cell is the surface epithelium, suggests a 
different pathophysiology to ulcerative colitis and there are important differences from 
ulcerative colitis in surgical outcomes, including a good response to segmental resection in 
selected cases and a generally poor response to pouch reconstruction. Taken together this 
implies a compelling need for isolated colonic Crohn’s disease to be identified separately 
from ileal/ileocolonic disease and from ulcerative colitis. This is particularly important when 
future therapeutic trials are designed and when cohort studies are reported. 
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LEGENDS TO FIGURES: 
1. Comparison between Crohn’s disease genetic risk score and ulcerative colitis genetic 
risk score for different locations of Crohn’s disease, ulcerative colitis and IBD unclassified 
(from Cleynen et al,17 with permission. This shows that isolated colonic Crohn’s lies 
approximately equidistant genetically between ileal Crohn’s disease and ulcerative 
colitis. 
 
2A. Isolated colonic Crohn’s as percentage of all Crohn’s disease by year in studies 
reporting sequential data from the same centres or geographical areas. 
2B. Isolated colonic Crohn’s disease as percentage of all Crohn’s disease by year in all 
studies. 
 
 
 
Supplementary Files 
1. PRISMA flow diagram.  
2. PRISMA checklist. 
  
Page 55 of 80
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 14
REFERENCES 
1. Bargen JA, Weber HM. Regional migratory chronic ulcerative colitis. Surg Gynecol Obstet 
1930;1:964-72. 
2. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis. A pathologic and clinical entity. 
J Amer Med Assoc 1932;99:1323-9. 
3. Moschcowitz E, Wilensky AO. Non-specific granulomata of the intestine. Am J Med Sci 
1923;166:48-66. 
4. Colp R. A case of nonspecific granuloma of the terminal ileum and caecum. Surg Clin N 
America 1934;14:443-9. 
5. Crohn BB, Rosenak BD. A combined form of ileitis and colitis. J Amer Med Assoc 
1936;106:1-7. 
6. Neuman HW, Bargen JA, Judd ES. A clinical study of two hundred and one cases of 
regional (segmental) colitis. Surg Gynecol Obstet 1954;99:563-71. 
7. Wells C. Ulcerative colitis and Crohn’s disease. Ann Roy Coll Surg Engl 1952;11:105-20. 
8. Goldgraber MB, Kirsner JB, Palmer WL. The histopathology of chronic ulcerative colitis 
and its pathogenic implications. Gastroenterology 1960;38:596-604. 
9. Lockhart-Mummery HE, Morson BC. Crohn’s disease (regional enteritis) of the large 
intestine and its distinction from ulcerative colitis. Gut 1960;1:87-105. 
10. Cornes JS, Stecher M. Primary Crohn’s disease of the colon and rectum. Gut 1961;2:189-
201. 
11. Truelove SC, Ellis H, Webster CD. The place of a double-barrelled ileostomy in ulcerative 
colitis and Crohn’s disease of the colon: a preliminary report. Brit Med J 1965;1:150-3. 
12. Burman JH, Thompson H, Cooke WT, et al. The effects of diversion of intestinal contents 
on the progress of Crohn’s disease of the large bowel. Gut 1971;12:11-15.  
13. Allan A, Andrews H, Hilton CJ, et al. Segmental colonic resection is an appropriate 
operation for short skip lesions due to Crohn's disease in the colon. World J Surg. 
1989;13:611-4.  
14. Reese GE, Lovegrove RE, Tilney HS, et al.  The effect of Crohn's disease on outcomes 
after restorative proctocolectomy. Dis Colon Rectum 2007;50:239-50. 
15. Price AB. Overlap in the spectrum on non-specific inflammatory bowel disease – “colitis 
indeterminate”. J Clin Pathol 1978;31:567-77. 
16. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory 
bowel disease: controversies, consensus and implications. Gut 2006;55:749-53. 
17. Cleynen I, Boucher G, Jostins L, et al. Inherited determinants of Crohn's disease and 
ulcerative colitis phenotypes: a genetic association study. Lancet 2016;387:156-67.  
18. Hadfield G. The primary histological lesion of regional ileitis. Lancet 1939;2:773–5. 
19. Warren BF. Classic pathology of ulcerative and Crohn’s colitis. J Clin Gastroenterol 
2004;38:S33-5. 
20. Morson BC. Crohn’s disease. Proc Roy Soc Med 1968;61:79-81. 
21. Krauss E, Agaimy A, Neumann H, et al.  Characterization of lymphoid follicles with red 
ring signs as first manifestation of early Crohn's disease by conventional  histopathology 
and confocal laser endomicroscopy. Int J Clin Exp Pathol 2012;5:411-21. 
22. Bull DM. Crohn’s disease of the colon. Gastroenterology 1979;76:607-21. 
23. Cook MG, Dixon MF. An analysis of the reliability of detection and diagnostic value of 
various pathological features in Crohn's disease and ulcerative colitis. Gut 1973;14:255-
62. 
24. Jones JH, Lennard-Jones JE, Morson BC, et al. Numerical taxonomy and discriminant 
Page 56 of 80
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 15
analysis applied to non-specific colitis. Q J Med 1973;42:715-32. 
25. Bentley E, Jenkins D, Campbell F, et al. How could pathologists improve the initial 
diagnosis of colitis? Evidence from an international workshop. J Clin Pathol 2002;55:955-
60. 
26. Fabricius PJ, Gyde SN, Shouler P, et al.  Crohn's disease in the elderly. Gut 1985;26:461-
5. 
27.  Harpaz N, Sachar DB. Segmental colitis associate with diverticular disease and other IBD 
look-alikes. J Clin Gastro 2006;40 (S3):S132-5. 
28. Rubio CA, Orrego A, Nesi G, et al. Frequency of epithelioid granulomas in colonoscopic 
biopsy specimens from paediatric and adult patients with Crohn's colitis. J Clin Pathol 
2007;60:1268-72 
29. Mahadeva U, Martin JP, Patel NK, et al. Granulomatous ulcerative colitis: a re- appraisal 
of the mucosal granuloma in the distinction of Crohn's disease from ulcerative colitis. 
Histopathology 2002;41:50-5.  
30. Louis E, Collard A, Oger AF, et al. Behaviour of Crohn’s disese according to the Vienna 
classification: changing patten over the course of he disease. Gut 2001;49:777-82. 
31. Chow DKL, Leong RWL, Lai LH, et al. Changes in Crohn’s disease phenotype over time in 
the Chinese population: Validation of the Montreal classification system. Inflamm Bowel 
Dis 2008;14:536-41. 
32. Vester-Andersen MK, Prosberg MV, Jess T, et al. Disease course and surgery rates in 
inflammatory bowel disease: a population-based, 7-year follow-up study in the era of 
immunomodulating therapy. Am J Gastroenterol 2014;109:705-14. 
33. Louis E, Michel V, Hugot JP, et al. Early development of stricturing or penetrating pattern 
in Crohn’s disease is influenced by disease location, number of flares, and smoking but 
not by NOD2/CARD15 genotype. Gut 2003;52:552-57. 
34. Lutgens MWMD, van Oijen MGH, van der Heijden GJMG et al. Declining risk of colorectal 
cancer in inflammatory bowel disease: an updated meta-analysis of population-based 
cohort studies. Inflamm Bowel Dis 2013;19:789-99. 
35. Kyle J. Crohn’s disease in the Northeastern and Northern Isles of Scotland: An 
epidemiological review. Gastroenterology 1992;103:392-9. 
36. Gunesh S, Thomas GA, Williams GT, et al. The incidence of Crohn's disease in Cardiff 
over the last 75 years: an update for 1996-2005. Aliment Pharmacol Ther 2008;27:211-9. 
37. Lapidus A, Bernell O, Hellers G, et al. Incidence of Crohn's disease in Stockholm County 
1955-1989. Gut 1997;41:480-6. 
38. Chouraki V, Savoye G, Dauchet L, et al. The changing pattern 
of Crohn's disease incidence in northern France: a continuing increase in the 10- to 19-
year-old age bracket (1988-2007). Aliment Pharmacol Ther 2011;33:1133-42. 
39. Gollop JH1, Phillips SF, Melton LJ 3rd, et al. Epidemiologic aspects of Crohn's disease: a 
population based study in Olmsted County, Minnesota, 1943-1982. Gut 1988;29:49-56. 
40. Loftus EV Jr, Silverstein MD, Sandborn WJ, et al. Crohn's disease in Olmsted County, 
Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology 
1998;114:1161-8. Erratum in: Gastroenterology 1999;116:1507. 
41. Humphreys WG1, Brown JS, Parks TG. Crohn's disease in Northern Ireland--a 
retrospective study of 440 cases. Ulster Med J 1990;59:30-5. 
42. Ekbom A, Helmick C, Zack M, et al. The epidemiology of inflammatory bowel disease: a 
large, population-based study in Sweden. Gastroenterology 1991;100:350-8. 
43. Yapp TR, Stenson R, Thomas GA, et al. Crohn's disease incidence in Cardiff from 1930: an 
Page 57 of 80
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 16
update for 1991-1995. Eur J Gastroenterol Hepatol 2000;12:907-11. 
44. Jayanthi V, Probert CS, Pinder D, et al. Epidemiology of Crohn's disease in Indian 
migrants and the indigenous population in Leicestershire. Q J Med 1992;82:125-38. 
45. Cottone M, Brignola C, Rosselli M, et al. Relationship between site of disease and familial 
occurrence in Crohn's disease. Dig Dis Sci 1997;42:129-32.  
46. Jacobsen BA, Fallingborg J, Rasmussen HH, et al. Increase in incidence and prevalence of 
inflammatory bowel disease in northern Denmark: a population-based study, 1978-
2002. Eur J Gastroenterol Hepatol 2006;18:601-6. 
47. Wright JP, Froggatt J, O'Keefe EA, et al. The epidemiology of inflammatory bowel disease 
in Cape Town 1980-1984. S Afr Med J 1986;70:10-5. 
48. Manninen P, Karvonen AL, Huhtala H, et al. The epidemiology of inflammatory bowel 
diseases in Finland. Scand J Gastroenterol 2010;45:1063-7.  
49. Economou M, Filis G, Tsianou Z, et al.  Crohn's disease incidence evolution in North-
western Greece is not associated with alteration of NOD2/CARD15 variants. World J 
Gastroenterol 2007;13:5116-20  
50. Rhodes JM, Cockel R, Allan RN, et al. Colonic Crohn's disease and the contraceptive pill. 
British Medical Journal 1984;288: 595-596. 
51. Gower-Rousseau C, Salomez JL, Dupas JL, et al. Incidence of inflammatory bowel disease 
in northern France (1988-1990). Gut 1994;35:1433-8. 
52. Auvin S, Molinié F, Gower-Rousseau C, et al. Incidence, clinical presentation and location 
at diagnosis of pediatric inflammatory bowel disease: a prospective population-based 
study in northern France (1988-1999). J Pediatr Gastroenterol Nutr 2005;41:49-55. 
53. Spanish Epidemiological and Economic Study Group on Crohn's disease. Epidemiological 
and clinical features of Spanish patients with Crohn's disease. Eur J Gastroenterol 
Hepatol 1999;11:1121-7. 
54. Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of 
inflammatory bowel disease during the last 5 decades: a population-based study from 
Copenhagen, Denmark. Inflamm Bowel Dis 2007;13:481-9. 
55. Chow DK, Leong RW, Lai LH, et al. Changes in Crohn's disease phenotype over time in 
the Chinese population:validation of the Montreal classification system. Inflamm Bowel 
Dis 2008;14:536-41. 
56. Romberg-Camps MJL, Dagnelle PC, Kester ADM, et al. Influence of phenotype at 
diagnosis and of other potential prognostic factors on the course of inflammatory bowel 
disease. Am J Gastroenterol 2009;104:371-83. 
57. Björnsson S, Tryggvason FÞ, Jónasson JG, et al.  Incidence of inflammatory bowel disease 
in Iceland 1995 - 2009. A nationwide population-based study. Scand J Gastroenterol 
2015;50:1368-75. 
58. Tozun N, Atug O, Imeryuz N, et al. Members of the Turkish IBD Study Group. Clinical 
characteristics of inflammatory bowel disease in Turkey: a multicenter epidemiologic 
survey. J Clin Gastroenterol 2009;43:51-7.  
59. Lakatos L, Kiss LS, David G, et al. Incidence, disease phenotype at diagnosis, and early 
disease course in inflammatory bowel diseases in Western Hungary, 2002-2006. Inflamm 
Bowel Dis 2011;17:2558-65.  
60. Nguyen GC, Torres EA, Regueiro M, et al.  Inflammatory bowel disease characteristics 
among African Americans, Hispanics, and non-Hispanic Whites: characterization of a 
large North American cohort. Am J Gastroenterol 2006;101:1012-23. 
Page 58 of 80
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 17
61. Ott C, Obermeier F, Thieler S, et al.  The incidence of inflammatory bowel disease in a 
rural region of Southern Germany: a prospective population-based study. Eur J 
Gastroenterol Hepatol 2008;20:917-23.  
62. Siddique I, Alazmi W, Al-Ali J, et al. Clinical epidemiology of Crohn's disease in Arabs 
based on the Montreal Classification. Inflamm Bowel Dis 2012;18:1689-97.  
63. Chen H, Lee A, Bowcock A, et al. Influence of Crohn's disease risk alleles and smoking on 
disease location. Dis Colon Rectum 2011;54:1020-5.  
64. Lucendo AJ, Hervías D, Roncero Ó, et al. Epidemiology and temporal trends (2000-2012) 
of inflammatory bowel disease in adult patients in a central region of Spain. Eur J 
Gastroenterol Hepatol 2014;26:1399-407.  
65. Henckaerts L, Pierik M, Joossens M, et al. Mutations in pattern recognition receptor 
genes modulate seroreactivity to microbial antigens in patients with inflammatory 
bowel disease. Gut 2007;56:1536-42. 
66. Herrinton LJ, Liu L, Lewis JD, et al. Incidence and prevalence of inflammatory bowel 
disease in a Northern California managed care organization, 1996-2002. Am J 
Gastroenterol 2008;103:1998-2006.  
67. Hancock L, Beckly J, Geremia A, et al.  Clinical and molecular characteristics of isolated 
colonic Crohn's disease. Inflamm Bowel Dis 2008;14:1667-77. 
68. Aloi M, Lionetti P, Barabino A, et al. SIGENP IBD Group. Phenotype and disease course of 
early-onset pediatric inflammatory bowel disease. Inflamm Bowel Dis 2014;20:597-605.  
69. Aljebreen AM, Alharbi OR, Azzam NA, et al. Clinical epidemiology and phenotypic 
characteristics of Crohn's disease in the central region of Saudi Arabia. Saudi J 
Gastroenterol 2014;20:162-9.  
70. Burisch J, Pedersen N, Cukovic-Cavka S, et al. Environmental factors in a population-
based inception cohort of inflammatory bowel disease patients in Europe--an ECCO-
EpiCom study. J Crohns Colitis 2014;8:607-16.  
71. Eglinton TW, Roberts R, Pearson J, et al.  Clinical and genetic risk factors for perianal 
Crohn's disease in a population-based cohort. Am J Gastroenterol 2012;107:589-96.  
72. Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease 
based on results from the Asia-pacific Crohn's and colitis epidemiology study. 
Gastroenterology 2013;145(1):158-165. 
73. Somerville KW, Logan RFA, Edmond M, et al. Smoking and Crohn’s disease. Brit Med J 
1984;289:954-6. 
74. Holdstock G, Savage D, Harman M, et al. Should patients with inflammatory bowel 
disease smoke? Brit Med J 1984;288:362. 
75. Tobin MV, Logan RFA, Langman MJS, et al.  Cigarette smoking and inflammatory bowel 
disease. Gastroenterology 1987;93:316-21. 
76. Lindberg E, Järnerot G, Huitfeldt B. Smoking in Crohn's disease: effect on localisation and 
clinical course. Gut 1992;33:779-82. 
77. Breuer-Katschinski B, Hollander N, Goebell H. Effect of cigarette smoking on the course 
of Crohn’s disease. Europ J Gastroenterol Hepatol 1996;8:225-8. 
78. Russel MG, Volovics A, Schoon EJ, et al. Inflammatory bowel disease: is there any 
relation between smoking status and disease presentation? European Collaborative IBD 
Study Group. Inflamm Bowel Dis 1998;4:182-6. 
79. Cosnes J, Carbonnel F, Carrat F, et al. Effects of current and former smoking on the 
clinical course of Crohn’s disease. Aliment Pharmacol Ther 1999;13:1403-11. 
80. Cosnes J, Nion-Larmurier I, Afchain P, et al. Gender differences in the response of colitis 
Page 59 of 80
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 18
to smoking. Clin Gatroenterol Hepatol 2004;2:41-8. 
81. Aldhous MC, Drummond HE, Anderson N, et al. Does cigarette smoking influence the 
phenotype of Crohn's disease? Analysis using the Montreal classification. Am J 
Gastroenterol 2007;102:577-88.  
82. Chen H, Lee A, Bowcock A, et al. Influence of Crohn's disease risk alleles and smoking on 
disease location. Dis Colon Rectum 2011;54:1020-5.  
83. Nunes T, Etchevers MJ, Domènech E, et al. Smoking does influence disease behaviour 
and impacts the need for therapy in Crohn's disease in the biologic era. Aliment 
Pharmacol Ther 2013;38:752-60. 
84. Chivese T, Esterhuizen TM, Basson AR. The Influence of Second-Hand Cigarette Smoke 
Exposure during Childhood and Active Cigarette Smoking on Crohn's Disease Phenotype 
Defined by the Montreal Classification Scheme in a Western Cape Population, South 
Africa. PLoS One 2015;10:e0139597.  
85. Cleynen I, Gonzalez JR, Figueroa et al. Genetic factors conferring an increased 
susceptibility to develop Crohn's disease also influence disease phenotype: results from 
the IBDchip European Project. Gut 2013;62:1556-65  
86. World Health Organisation. WHO Report on the global tobacco epidemic 2008: The 
MPOWER package. www.who.int/tobacco/mpower/2008/en/  
87. Cosnes J, Carbonnel F, Beaugerie L, et al. Effects of cigarette smoking on the long-term 
course of Crohn's disease. Gastroenterology 1996;110:424-31. 
88. To N, Gracie DJ, Ford AC. Systematic review with meta-analysis: the adverse effects of 
tobacco smoking on the natural history of Crohn's disease. Aliment Pharmacol Ther 
2016;43:549-61.  
89. Cornish JA, Tan E, Simillis C, et al.  The risk of oral contraceptives in the etiology of 
inflammatory bowel disease: a meta-analysis. Am J Gastroenterol 2008;103:2394-400.  
90. Vessey M, Jewell D, Smith A, et al. Chronic inflammatory bowel disease, cigarette 
smoking, and use of oral contraceptives: findings in a large cohort study of women of 
childbearing age. Br Med J 1986;292:1101-3. 
91. Lashner BA, Kane SV, Hanauer SB. Lack of association between oral contraceptive use 
and Crohn's disease: a community-based matched case-control study. Gastroenterology 
1989;97:1442-7. 
92. Sandler RS, Wurzelmann JI, Lyles CM. Oral contraceptive use and the risk of 
inflammatory bowel disease. Epidemiology 1992;3:374-8 
93. Persson PG, Leijonmarck CE, Bernell O, et al.  Risk indicators for inflammatory bowel 
disease. Int J Epidemiol 1993;22:268-72. 
94. Katschinski B, Fingerle D, Scherbaum B, et al. Oral contraceptive use and cigarette 
smoking in Crohn's disease. Dig Dis Sci 1993;38:1596-600. 
95. Khalili H, Higuchi LM, Ananthakrishnan AN, et al. Oral contraceptives, reproductive 
factors and risk of inflammatory bowel disease. Gut 2013;62:1153-9.  
96. Khalili H, Chan AT. Author response: oral contraceptives and Crohn's disease. Gut 
2015;64:854.   
97. Kilpatrick ZM, Silverman JF, Betancourt E, et al. Vascular occlusion of the colon and oral 
contraceptives. Possible relation. N Engl J Med 1968;278:438-40.  
98. Rasmussen DK, Segars LW. Case of ischemic colitis in a young adolescent associated with 
triphasic hormonal contraceptive therapy: a case report and review of the literature. W 
V MedJ 2011;107:22-5.  
99. Deana DG1, Dean PJ. Reversible ischemic colitis in young women. Association with oral 
Page 60 of 80
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 19
contraceptive use. Am J Surg Pathol 1995;19:454-62.  
100. Tedesco FJ, Volpicelli NA, Moore FS. Estrogen- and progesterone-associated colitis: a 
disorder with clinical and endoscopic features mimicking Crohn's colitis. Gastrointest 
Endosc 1982;28:247-9.  
101. Tsai HH, Howden CW, Thomson TJ. Probable Crohn's colitis mimicking ischaemic 
colitis in a young adult. Scott Med J 1989;34:406-7 
102. Alic M. Epidemiology supports oral contraceptives as a risk factor in Crohn's disease. 
Gut 2000;46:140  
103. Economou M1, Trikalinos TA, Loizou KT, et al. Differential effects of NOD2 variants 
on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J 
Gastroenterol 2004;99:2393-404.  
104. Ahmad T, Marshall SE, Jewell D. Genetics of inflammatory bowel disease: The role of 
the HLA complex. World J Gastroenterol 2006;12:3628-35.  
105. Paul T, Birnbaum A, Pal DK, et al.  Distinct phenotype of early childhood 
inflammatory bowel disease. J Clin Gastroenterol 2006;40:583-6. 
106. Maisawa S, Sasaki M, Ida S, et al. Characteristics of inflammatory bowel disease with 
an onset before eight years of age: a multicenter epidemiological survey in Japan. J 
Gastroenterol Hepatol 2013;28:499-504. 
107. Marks DJ, Miyagi K, Rahman FZ, et al. Inflammatory bowel disease in CGD 
reproduces the clinicopathological features of Crohn's disease.  Am J Gastroenterol 
2009;104:117-24. 
108. Uhlig HH, Schwerd T, Koletzko S, et al.  The diagnostic approach to monogenic very 
early onset inflammatory bowel disease. Gastroenterology 2014;147:990-1007. 
109. Moran CJ1, Klein C, Muise AM, et al.  Very early-onset inflammatory bowel disease: 
gaining insight through focused discovery. Inflamm Bowel Dis 2015;21:1166-75.  
110. Zeissig Y, Petersen BS, Milutinovic S, et al. XIAP variants in male Crohn's disease. Gut 
2015;64:66-76. 
111. Elkadri AA, Stempak JM, Walters TD, et al.. Serum antibodies associated with 
complex inflammatory bowel disease. Inflamm Bowel Dis 2013;19:1499-505.  
112. Zhang Z, Li C, Zhao X, Lv C, et al. Anti-Saccharomyces cerevisiae antibodies associate 
with phenotypes and higher risk for surgery in Crohn's disease: a meta-analysis. Dig Dis 
Sci 2012;57:2944-54. 
113. Kaul A, Hutfless S, Liu L, et al.  Serum anti-glycan antibody biomarkers for 
inflammatory bowel disease diagnosis and progression: a systematic review and meta-
analysis. Inflamm Bowel Dis 2012;18:1872-84.  
114. Reese GE, Constantinides VA, Simillis C, et al.  Diagnostic precision of anti-
Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic 
antibodies in inflammatory bowel disease. Am J Gastroenterol 2006;101:2410-22. 
115. Duerr RH, Targan SR, Landers CJ, et al. Anti-neutrophil cytoplasmic antibodies in 
ulcerative colitis. Comparison with other colitides/diarrheal illnesses. Gastroenterology 
1991;100:1590-6. 
116. Cambridge G, Rampton DS, Stevens TR, et al. Anti-neutrophil antibodies in 
inflammatory bowel disease: prevalence and diagnostic role. Gut 1992;33:668-74. 
117. Joossens S, Reinisch W, Vermeire S, et al. The value of serologic markers in 
indeterminate colitis: a prospective follow-up  study. Gastroenterology 2002;122:1242-
7. 
Page 61 of 80
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 20
118. Lawrance IC, Murray K, Hall A, et al. A prospective comparative study of ASCA and 
pANCA in Chinese and Caucasian IBD patients. Am J Gastroenterol 2004;99:2186-94. 
119. Annese V, Piepoli A, Perri F, et al. Anti-Saccharomyces cerevisiae mannan antibodies 
in inflammatory bowel disease: comparison of different assays and correlation with 
clinical features. Aliment Pharmacol Ther 2004;20:1143-52. 
120. Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in 
inflammatory bowel disease are associated with complicated disease behaviour. Gut 
2007;56:1394-403.  
121. Vind I, Riis L, Jespersgaard C, Jess T, et al. Genetic and environmental factors as 
predictors of disease severity and extent at time of diagnosis in an inception cohort of 
inflammatory bowel disease, Copenhagen County and City 2003-2005. J Crohns Colitis 
2008;2:162-9.  
122. Lakatos PL, Altorjay I, Szamosi T, et al. Pancreatic autoantibodies are associated with 
reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and 
extraintestinal ma ifestations, but not with NOD2/CARD15 or TLR4 genotype in a 
Hungarian IBD cohort. Inflamm Bowel Dis 2009;15:365-74.  
123. Bogdanos DP, Roggenbuck D, Reinhold D, et al. Pancreatic-specific autoantibodies to 
glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's 
disease. BMC Gastroenterol 2012;12:102. 
124. Bertin D, Grimaud JC, Lesavre N, et al.  Targeting tissular immune response improves 
diagnostic performance of anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's 
disease. PLoS One 2013;8:e80433.  
125. Prideaux L, De Cruz P, Ng SC, et al.  Serological antibodies in inflammatory bowel 
disease: a systematic review. Inflamm B wel Dis 2012;18:1340-55. 
126. Hold G, Smith M, Grange C, et al. Role of the gut microbiota in inflammatory bowel 
disease pathogenesis: What have we learnt in the past 10 years? World J Gastro 
2014;20:1192-1210. 
127. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: 
current status and the future ahead. Gastroenterology 2014;146:1489-99.  
128. Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-
onset Crohn's disease. Cell Host Microbe 2014;15:382-92.  
129. Baumgart M, Dogan B, Rishniw M, et al. Culture independent analysis of ileal mucosa 
reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to 
depletion of Clostridiales in Crohn's disease involving the ileum. ISME J 2007;1:403-18. 
130. Willing BP, Dicksved J, Halfvarson J, Andersson AF, Lucio M, Zheng Z, Järnerot G, Tysk 
C, Jansson JK, et al.. A pyrosequencing study in twins shows that gastrointestinal 
microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 
2010;139:1844-1854. 
131. Willing B, Halfvarson J, Dicksved J, et al. Twin studies reveal specific imbalances in 
the mucosa-associated microbiota of patients with ileal Crohn's disease. Inflamm Bowel 
Dis 2009;15:653-60. 
132. Lopez-Siles M, Martinez-Medina M, Busquets D, et al. Mucosa-associated 
Faecalibacterium prausnitzii and Escherichia coli co-abundance can distinguish Irritable 
Bowel Syndrome and Inflammatory Bowel Disease phenotypes. Int J Med Microbiol 
2014;304:464-75.  
133. Naftali T, Reshef L, Kovacs A, et al. Distinct Microbiotas are Associated with Ileum-
Restricted and Colon-Involving Crohn's Disease. Inflamm Bowel Dis 2016;22:293-302. 
Page 62 of 80
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 21
134. Haberman Y, Tickle TL, Dexheimer PJ, et al. Pediatric Crohn disease patients exhibit 
specific ileal transcriptome and microbiome signature. J Clin Invest 2014;124:3617-33. 
Erratum in: J Clin Invest 2015;125:1363. 
135. Ford AC, Kane SV, Khan KJ, et al. Efficacy of 5-aminosalicylates in Crohn's disease: 
systematic review and meta-analysis. Am J Gastroenterol 2011;106:617-29. 
136. Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in 
Crohn's disease. Cochrane Database Syst Rev 2010;(12):CD008870. 
137. Moja L, Danese S, Fiorino G, et al. Systematic review with network meta-analysis: 
comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's 
disease. Aliment Pharmacol Ther 2015;41:1055-65.  
138. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-
induced remission in Crohn's Disease. Cochrane Database Syst Rev 2005;(1):CD003715.  
139. Ford AC, Khan KJ, Talley NJ, et al. 5-aminosalicylates prevent relapse of Crohn's 
disease after surgically induced remission: systematic review and meta-analysis. Am J 
Gastroenterol 2011;106:413-20.  
140. Singleton JW, Hanauer SB, Gitnick GL, et al.  Mesalamine capsules for the treatment 
of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study 
Group. Gastroenterology 1993;104:1293-301.  
141. International Mesalazine Study Group. Coated oral 5-aminosalicylic acid versus 
placebo in maintaining remission of inactive Crohn's disease. Aliment Pharmacol Ther 
1990;4:55-64.  
142. Prantera C, Pallone F, Brunetti G, et al. Oral 5-aminosalicylic acid (Asacol) in the 
maintenance treatment of Crohn's disease. The Italian IBD Study Group. 
Gastroenterology 1992;103:363-8.  
143. Gendre JP, Mary JY, Florent C, et al. Oral mesalamine (Pentasa) as maintenance 
treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe 
d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). 
Gastroenterology 1993;104:435-9.  
144. de Franchis R, Omodei P, Ranzi T, et al.  Controlled trial of oral 5-aminosalicylic acid 
for the prevention of early relapse in Crohn's disease. Aliment Pharmacol Ther 
1997;11:845-52.  
145. Mahmud N, Kamm MA, Dupas JL, et al.  Olsalazine is not superior to placebo in 
maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, 
randomised, multicentre study. Gut 2001;49:552-6.  
146. Singleton JW, Summers RW, Kern F Jr, et al.  A trial of sulfasalazine as adjunctive 
therapy in Crohn's disease. Gastroenterology 1979;77:887-97.  
147. Summers RW, Switz DM, Sessions JT Jr, et al.  National Cooperative Crohn's Disease 
Study: results of drug treatment. Gastroenterology 1979;77:847-69.  
148. Malchow H, Ewe K, Brandes JW, et al.  European Cooperative Crohn's Disease Study 
(ECCDS): results of drug treatment. Gastroenterology 1984;86:249-66. 
149. Khan, K.J., Ullman TA, Ford AC et al., Antibiotic therapy in inflammatory bowel 
disease: a systematic review and meta-analysis. Am J Gastroenterol  2011;106: 661-73. 
150. Nitzan, O., Elias M, Peretz A et al., Role of antibiotics for treatment of inflammatory 
bowel disease. World J Gastroenterol 2016;22:1078-87. 
151. Su, JW, Ma JJ, Zhang HJ. Use of antibiotics in patients with Crohn's disease: a 
systematic review and meta-analysis. J Dig Dis 2015;16:58-66.  
152. Prantera C, Lochs H, Grimaldi M et al. Rifaximin-extended intestinal release induces 
Page 63 of 80
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 22
remission in patients with moderately active Crohn's disease. Gastroenterology 2012; 
142:473-481. 
153. Blichfeldt, P, Blomhoff JP, Myhre E, et al. Metronidazole in Crohn's disease. A double 
blind cross-over clinical trial. Scand J Gastroenterol 1978;13:123-7. 
154. Sutherland L, Singleton J, Sessions J et a., Double blind, placebo controlled trial of 
metronidazole in Crohn's disease. Gut 1991;32:1071-5. 
155. Steinhart AH, Feagan BG, Wong CJ et al. Combined budesonide and antibiotic 
therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 
2002;123:33-40. 
156. Selby W, Pavli P, Crotty B et al. Two-year combination antibiotic therapy with 
clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 
2007;132:2313-9. 
157. Tromm A, Bunganic I, Tomsova E, et al. Budesonide 9 mg is at least as effective as 
mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease. 
Gastroenterology  2011;140:425-434.  
158. Bar-Meir S, Chowers Y, Lavy A, et al., Budesonide versus prednisone in the treatment 
of active Crohn's disease. The Israeli Budesonide Study Group. Gastroenterology 
1998;115:835-40.  
159. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric 
monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's 
Disease cA2 Study Group. N Engl J Med 1997; 337: 1029–35. 
160. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's 
disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541–9. 
161. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor 
monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. 
Gastroenterology 2006; 130: 323–33. 
162. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance 
treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56: 1232–9. 
163. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn’s 
disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 
146: 829–38. 
164. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of 
clinical response and remission in patients with Crohn's disease: the CHARM trial. 
Gastroenterology 2007; 132: 52–65. 
165. Sandborn WJ, Melmed GU, Mcgovern DP et al. Certolizumab pegol for active Crohn's 
disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol 2011; 9:670-
678. 
166. Arnott, I.D., McNeill G, Satsangi J. An analysis of factors influencing short-term and 
sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther 
2003;17:1451-7. 
167. Laharie D, Salzmann M, Boubekeur H et al. Predictors of response to infliximab in 
luminal Crohn's disease. Gastroenterol Clin Biol 2005;29:145-9. 
168. Vermeire S, Louis E, Carbonez A et al. Demographic and clinical parameters 
influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment 
in Crohn's disease. Am J Gastroenterol 2002;97:2357-63. 
Page 64 of 80
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 23
169. Dupont-Lucas C, Sternszus R, Ezri J et al. Identifying patients at high risk of loss of 
response to infliximab maintenance therapy in paediatric Crohn's disease. J Crohns 
Colitis 2016;10:795-804. 
170. Cohen RD, Lewis JR, Turner H et al. Predictors of adalimumab dose escalation in 
patients with Crohn's disease at a tertiary referral center. Inflamm Bowel Dis 
2012;18:10-6. 
171. Sandborn,WJ, Feagan BG, Rutgeerts P et al. Vedolizumab as induction and 
maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711-21. 
172. Kansal S, Wagner J, Kirkwood CD, et al. Enteral nutrition in Crohn's disease: an 
underused therapy. Gastroenterol Res Pract 2013;2013:482108. 
173. Lee D, Albenberg L, Compher C, et al. Diet in the pathogenesis and treatment of 
inflammatory bowel diseases. Gastroenterology 2015;148:1087-106. 
174. El-Matary W, Otley A, Critch J, et al. Enteral Feeding Therapy for Maintaining 
Remission in Crohn's Disease: A Systematic Review. J Parenter Enteral Nutr 2015; Dec 8. 
pii: 0148607115621051 
175. Dickinson RJ, Ashton MG, Axon AT, et al. Controlled trial of intravenous 
hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute 
colitis. Gastroenterology 1980;79:1199-204. 
176. González-Huix F, Fernández-Bañares F, Esteve-Comas M, et al. Enteral versus 
parenteral nutrition as adjunct therapy in acute ulcerative colitis. Am J Gastroenterol 
1993;88:227-32. 
177. Lochs H, Steinhardt HJ, Klaus-Wentz B, et al.Comparison of enteral nutrition and 
drug treatment in active Crohn's disease. Results of the European Cooperative Crohn's 
Disease Study. IV. Gastroenterology 1991;101:881-8. 
178. Wilschanski M, Sherman P, Pencharz P, et al. Supplementary enteral nutrition 
maintains remission in paediatric Crohn's disease. Gut 1996;38:543-8. 
179. Afzal NA, Davies S, Paintin M, et al. Colonic Crohn's disease in children does not 
respond well to treatment with enteral nutrition if the ileum is not involved. Dig Dis Sci 
2005;50:1471-5. 
180. Buchanan E, Gaunt WW, Cardigan T, et al. The use of exclusive enteral nutrition for 
induction of remission in children with Crohn's disease demonstrates that disease 
phenotype does not influence clinical remission. Aliment Pharmacol Ther 2009;30:501-7. 
181. Rubio A, Pigneur B, Garnier-Lengliné H, et al.  The efficacy of exclusive nutritional 
therapy in paediatric Crohn's disease, comparing fractionated oral vs. continuous enteral 
feeding. Aliment Pharmacol Ther 2011;33:1332-9. 
182. de Bie C, Kindermann A, Escher J. Use of exclusive enteral nutrition in paediatric 
Crohn's disease in the Netherlands. J Crohn's Colitis 2013;7:263-70. 
183. Harper PH, Lee EC, Kettlewell MG, et al. Role of the faecal stream in the 
maintenance of Crohn's colitis. Gut 1985;26:279-84. 
184. Harper PH, Truelove SC, Lee EC et al. Split ileostomy and ileocolostomy for Crohn's 
disease of the colon and ulcerative colitis: a 20 year survey. Gut 1983;24:106-13. 
185. Allan A, Andrews H, Hilton CJ, et al. Segmental colonic resection is an appropriate 
operation for short skip lesions due to Crohn's disease in the colon. World J Surg 
1989;13:611-4. 
186. Andersson P, Olaison G, Hallböök O, et al. Segmental resection or subtotal colectomy 
in Crohn's colitis? Dis Colon Rectum 2002;45:47-53. 
187. Bernell O, Lapidus A, Hellers G. Recurrence after colectomy in Crohn's colitis. Dis 
Page 65 of 80
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 24
Colon Rectum 2001;44:647-54. 
188. Martin ST, Vogel JD. Restorative procedures in colonic crohn disease. Clin Colon 
Rectal Surg 2013;26:100-5. 
189. Kiran RP, Nisar PJ, Church JM, et al.The role of primary surgical procedure in 
maintaining intestinal continuity for patients with Crohn's colitis. Ann Surg 
2011;253:1130-5. 
190. Schwarz RJ, Pezim ME. Failure of right-sided coloanal anastomosis for treatment of 
left-sided ulcerative colitis. Report of a case. Dis Colon Rectum 1991;34:618-21. 
191. Maser EA, Sachar DB, Kruse D, et al. High rates of metachronous colon cancer or 
dysplasia after segmental resection or subtotal colectomy in Crohn's colitis. Inflamm 
Bowel Dis 2013;19:1827-32. 
192. Tekkis PP, Heriot AG, Smith O, et al. Long-term outcomes of restorative 
proctocolectomy for Crohn's disease and indeterminate colitis. Colorectal Dis 
2005;7:218-23. 
193. Fazio VW, Kira  RP, Remzi FH, et al.  Ileal pouch anal anastomosis: analysis of 
outcome and quality of life in 3707 patients. Ann Surg 2013;257:679-85. 
  
  
Page 66 of 80
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 25
Authors/ref Country Years 
analysed 
Number 
of 
cases 
all CD 
All CD 
% 
female  
Isolated 
colonic CD 
as % of total 
CD  
Isolated 
colonic 
CD % 
female 
CD 
excluding 
Isolated 
colonic 
% female 
(calculated) 
Median Age 
at 
presentation 
(colonic CD) 
unspecified or 
indeterminate 
as ratio to 
colonic CD in 
same series 
Cornes10 UK 1961 131 46 34 60 38 41-50 - 
Gollop39 USA 1943-
82 
103 64 36 68 62 25-34 - 
Loftus40 USA 1940-
93 
225 54 32 - - - - 
Humphreys41 UK 1966-
81 
440 58 40 - - - - 
Ekbom42 Sweden 1965-
83 
1469 53 25 - - 33 (mean) - 
Kyle35 UK 1955-
88 
856 63 41 63 63 40-49 - 
“ “ “ “ 1964-
69 
122 - 30 - - - - 
“ “ “ “ 1970-
75 
167 - 40 - - - - 
“ “ “ “ 1976-
81 
204 - 46 - - - - 
“ “ “ “ 1982-
87 
263 - 54 - - - - 
Lapidus37 Sweden 1955-
59 
83 61 14 - - - - 
  1960-
64 
145 48 15 - - - - 
  1965-
69 
270 51 21 - - - - 
  1970-
74 
364 53 26 - - - - 
  1975-
79 
331 54 26 - - - - 
  1980-
84 
348 58 32 - - - - 
  1985-
89 
395 49 32 - - - - 
Gunesh36 UK 
(Cardiff) 
1950-
60 
40 - 13 - - - - 
“ “ “ “ 1960-
70 
89 - 17 - - - - 
“ “ “ “ 1970-
80 
148 - 34 - - - - 
“ “ “ “ 1980-
90 
217 - 38 - - - - 
Yapp43 UK (Cardiff) 1991-
95 
84 68 43 - - - - 
Gunesh36 “ “ 1996-
2005 
212 61 43 68 55 - - 
Jayanthi44 UK 1972-
89 
235 50 25 
(incr from 
1972 to 89) 
- - - - 
Cottone45 Italy 1975-
95 
882 - 18 - - - - 
Jacobsen46 Denmark 1978-
87 
196 67 
(1978-
87) 
32 - - - - 
“ “ “ “ 1988-
97 
354 “ “ 42 - - - - 
“ “ “ “ 1998-
2002 
230 “ “ 51 - - - - 
Wright47 S.Africa 1980-
84 
134 69 27 - - - 0.44 
Manninen48 Finland 1986-
99 
470 50 40% 1986 
31% 1999 
- - - 0.56 
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Economou49 Greece 1983-
2005 
105 37 40 - - - 0.40 
Rhodes50 UK 1984 395 55 22 72 50 28 
(subset) 
- 
Gower-
Rousseau51 
France 1994 674 57 19 - - 28 1.15 
Auvin52 France 1988-
99 
367 
(< 17y) 
47 10 - - - 0.54 
Spanish53 Spain 1997 635 52 17 - - - - 
Jess54 Denmark 1962-
87 
374 58 30 - - - - 
“ “ “ “ 1991-
93 
58 66 43 - - - - 
“ “ “ “ 2003-
04 
209 54 37 - - - - 
Chow55 China 1987-
2005 
109 29 35 - - - - 
Chouraki38 France 1988-
2007 
7409 56 11 - - - 0.90 
“ “ “ “ 1988-
90 
544 - 23 - - - - 
“ “ “ “ 1997-
99 
1044 - 13 - - - - 
“ “ “ “ 2006-
07 
533 - 5 - - - - 
Romberg-
Camps56 
Netherlands 1991-
2003 
476 61 27 66 59 34 (mean) 0.63 
Bjornsson57 Iceland 1995-
2009 
279 54 55 - - - 0.08 
Tozun58 Turkey 2001-
03 
216 44 26 - - - - 
Lakatos59 Hungary 2002-
06 
163 48 36  -   
Nguyen60 USA/Canada 2003-
05 
579 - 19 - - - 0.30 
Ott61 Germany 2004-
06 
168 55 18 - - - 0.43 
Siddique62 Kuwait 2005-6 206 52 14 - - - - 
Chen63 USA 2005-
10 
628 55 21 50 56 - - 
Lucendo64 Spain 2000-
12 
599 49 24 - - - 0.10 
Henckaerts65 Belg 2007 874 - 17 - - - 0.03 
Herrinton66 USA 2008 948 55 40 - - - 0.10 
Hancock67 UK 2008 675 62 20 
(“enriched”) 
74 59 31 (mean) - 
Aloi68 Italy 2009-
13 
10 
(<5y) 
- 50 - - - - 
“ “ “ “ “ “ 215 
(6-18y) 
- 15 - - - 1.00 
Aljebreen69 Saudi 2009-
13 
497 41 8 - - - - 
Burisch70 Western 
europe 
2010 345 48 26 - - - 1.19 
“” “” Eastern 
europe 
2010 99 41 20 - - - 0.30 
Eglinton71 NZ 2011 507 63 42 - - - - 
Ng72 Asia-pacific 2011-
12 
166 Asia 
39% 
Austr 
52% 
24 - - - 0.53 
Cleynen17 16 countries 2015 16,902 56 24 - - - 0.06 
 
 
Table 1. Studies of Crohn’s disease age and sex distribution and proportion of total,  where 
isolated colonic Crohn’s disease separately identified (in approximate median date order). 
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• “current smoking” variably either smoking at time of diagnosis or at time of sampling but excluding “ex-smoking” 
 
Table 2. Studies of smoking in Crohn’s disease where isolated colonic disease separately 
identified 
  
Author/ref Year Country Number of 
cases CD 
Nature of study Current smoking OR/RR for 
CD phenotype 
Current 
smoking * 
isolated 
colonic CD 
% 
Current 
smoking all 
CD% 
Current 
smoking 
CD 
excluding 
isolated 
colonic % 
Current 
smoking 
healthy 
controls % 
Current 
smoking 
UC % 
Somerville73 1984 UK 82 Case control RR for smoking and CD: 
Small bowel only 3.5 (0.8-
14.6) 
Colon only 4.7 (1.4-16.1) 
Small and large bowel 4.5 
(1.8-11.5) 
- 56 - 26 - 
Holdstock74 1984 UK 150 Consecutive 
outpatients 
- 25 
(smokers 
with isolated 
colon CD 
had more 
relapses 
P=0.028) 
35 52 - 8 
Tobin75 1987 UK 137 Case control RR for smoking at onset 
and CD: 
Small bowel only 1.4 (0.5-
4.0) 
Ileum and asc colon 6.0 
(2.1-17.2) 
Small bowel and rest of 
colon 3.9 (1.5-10.2) 
Colon only 2.5 (0.8-7.3) 
- 47 - 33 
(controls 
for UC 
40%) 
11 
Lindberg76 1992 Sweden 231 Postal 
questionnaire 
(95% 
response) 
- 42 51 53 - - 
Breuer-
Katschinski77 
1995 Germany 346 Postal 
questionnaire 
(82% 
response) 
- 49 50 49 - - 
Russel78 1998 Europe 
(20 
centres, 
13 
countries) 
457 Prospective 
consecutive 
cases 
- 35 47 59 - 16 
Cosnes79 1999 France 622 Consecutive 
outpatients 
- 54 49 49 - - 
Cosnes80 2004 France 688 all 
colonic 
Consecutive 
outpatients 
- 61 -  - 42 
Aldhous81 2007 UK 
(Scotland) 
408 Retrospective 
outpatients 
- 33 43 50 - - 
Hancock67 2008 UK 675 Database OR 1.64 (1.09-2.45) for 
never smokers with isolated 
colonic CD vs ileal or 
ileocolonic 
51 
(ever) 
61 
(ever) 
63 - - 
Chen82 2011 USA 628 University 
database 
OR 1.69 (1.07-2.66) for any 
ileal involvement (L1+L3) 
vs colon only (L2) 
25 37 38 - - 
Nunes83 2013 Spain 3224 National 
registry 
- 26 34 35 - - 
Chivese84 2015 S. Africa 194 Prospective 
consecutive 
cases 
RR 3.63 (1.32-9.98) 
for ileo-colonic vs colonic; 
RR 3.54 (1.06-11.83) 
for ileal vs colonic 
62 73 79 - - 
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Author/Ref Study design N (total CD) n/% isolated 
colonic CD taking 
OC at onset 
n/% all other CD 
taking OC at 
onset 
OR/RR (95%CI) for 
OC use compared 
with healthy 
controls (when 
documented by 
disease location) 
OC use in 
isolated 
colonic vs all 
other CD 
Rhodes50 Case control 
matched for 
age and year of 
onset 
37 9/12 75% 11/25  44% - NS Increased 
P=0.09 
 
Vessey90 Cohort study in 
patients 
attending family 
planning clinics 
18 4/7 57% 4/11 36% - NS increased 
0.63 
Lashner91 Case control 51 (incl 8 
isolated colonic) 
- - Isolated colonic  
OR0.50(0.05–5.26) 
 
Small bowel only 
1.25 (0.34–4.64) 
 
Ileocolonic 
0.56(0.20-1.52)  
 
 
NS reduced 
(and no 
significant 
association in 
this study 
between OC 
use and any 
Crohns) 
Sandler92 Case control 
Age matched 
and excluding 
onset before 
menarche 
184 (incl 26 
isolated colonic) 
- - Isolated colonic 
OR2.63 (1.00-7.11) 
 
Small bowel only 
1.33 (0.70-2.53) 
 
Ileocolonic 1.52 
(0.82-2.83) 
NS increased 
Persson93 Case control 
age and sex 
matched 
152 - - Isolated colonic 
RR 3.6 (1.1-12.2) 
 
Small bowel only 
0.8 (0.3-2.4) 
 
Ileocolonic 
1.7 (0.8-4.0) 
NS increased 
Katschinski94 Case control 
pre-
menopausal  
90 
(incl 30 isolated 
colonic) 
- - Isolated colonic 
RR3.2 (1.1-15.3) 
 
Small bowel only 
RR4.7 (1.6-17.8) 
 
Ileocolonic 
RR 3.8 (1.3 -17.0) 
NS reduced 
Khalili95,96 Cohort – 
Nurses Health 
315 (incl 141 
isolated colonic) 
- - Isolated colonic 
HR4.13 (1.77-9.68) 
 
Ileal only 
HR2.99 (1.06-8.49) 
NS increased 
 
Table 3 – Studies of oral contraceptive usage in Crohn’s disease where isolated colonic 
disease separately identified. 
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Author/Ref Year Study design N (isolated 
colonic 
CD) 
ASCA 
IgA 
(n/%) 
ASCA 
IgG 
(n/%) 
ASCA (IgG 
or IgA) 
(n/%) 
pANCA 
(n/%) 
ompC 
(n/%) 
GP2 UC results in same 
study 
Comments 
Duerr115 1991 Prospective  18 - - - 5/18 
(28%) 
- - pANCA 34/40 (85%) pANCA+ in isolated colonic CD 
not signif commoner than  
diarrhea-predom IBS (4/27 
15%) 
Cambridge116 1992 Stored sera 
IBD and 
healthy 
controls 
18 - - - 1/18 
(6%) 
- - pANCA 27/50 (54%) pANCA+ in 4/32 CD with small 
bowel involvt 
Joossens117 2002 Prospective 
follow-up of 
97 patients 
with initial 
diag of 
indeterminat
e colitis 
17 NA NA 10/17 
(59%) 
6/17 
(35%) 
- - ASCA+ in 3/14 (21%) 
pANCA+ in 8/14 (57%) 
All patients initially 
indeterminate 
Lawrance118 2004 Prospective 
Caucasian 
and Chinese 
35 6/35 
(18%) 
9/35 
(26%) 
NA NA - - ASCA IgA 6/100 
ASCA IgG 11/100 
ASCA less likely positive in 
isolated colonic CD than CD 
with ileal involvement 
Annese119 2004 Prospective 61 NA NA 25/61 
(41%) 
- - - ASCA 32/197 (16%) ASCA in CD overall 51% 
Ferrante120 2007 Prospective 
study IBD 
plus non-IBD 
and healthy 
controls 
70 NA 6% NA 21% 3.5% - ASCA IgG 9.6% 
pANCA 37% 
All antimicrobial abs lower titre 
in isolated colonic CD  than 
other CD 
Vind121 2008 Prospective 
cohort 
60 NA NA 5/60 (8%) 15/60 
(25%) 
- - ASCA 14% 
pANCA 55% 
ASCA CD overall 22% 
Lakatos122 2009 Cohort 143 NA NA NA NA - - ASCA(either IgA or 
IgG)+/pANCA- 
combination in 9% UC 
ASCA(either IgA or 
IgG)+/pANCA- combination in 
52% isolated colonic CD 
Bogdanos123 2012 Prospective 
paediatric  
32 NA NA 5/32 (16%) - - 2/32 
(6.2%) 
GP2 9/102 (8.8%) 
ASCA 7/102 (7%) 
GP2 ab (IgG or IgA) in 49/137 
(35.8%) other (nonL2) CD 
ASCA 55/137 (40.1%) other 
(nonL2) CD 
Bertin124 2013 Prospective 
recruited at 
colonoscopy 
67 NA NA 21/67 
(31%) 
- 15/67 
(22%) 
- ompC 2/35 (6%) 
ASCA 5/35 (14%) 
Colon mucosal culture 
supernatant ab measures 
discriminated better between 
L2 CD and UC 
Elkadri111 2013 Prospective 
cohort adults 
and children 
55 NA NA NA but OR 
0.25 (0.12-
0.51; 
P=0.0002) 
for assocn 
with 
isolated 
colonic 
disease vs 
other sites 
NA but 
OR 2.27 
(1.50 – 
4.92; 
P<0.03 
for 
assocn 
with 
isolated 
colonic 
disease 
42.7% all 
CD, 
isolated 
CD NA 
- ASCA (either IgA or 
IgG) in 12.1% UC; 
62.9% CD; 
pANCA in 55.6% UC, 
14.3% CD; 
anti-OmpC in 28.0% 
UC, 42.7% CD 
ASCA positivity less common in 
isolated colonic CD than other 
sites 
 
 
Table 4. Serological test results in isolated colonic Crohn’s disease and ulcerative colitis.  
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*Though the study included patients with isolated colonic CD, results were pooled for patients with colonic involvement 
#Willing 2010, similar patient cohort to Willing (2009) but sequencing methodology compared to terminal-restriction fragment length polymorphism in Willing 
(2009).  
‡FE index was calculated as [log10 (F/Hc) − log10 (E/Hc)/log10 (TB/Hc), F being the 16S rRNA gene copies of F. prausnitzii, E the 16S rRNA gene copies of 
E. coli, Hc a million of human cells, and TB a million of 16S rRNA gene copies of total bacteria.  
 
Table 5: Studies of mucosal microbiota in Crohn’s disease where isolated colonic disease 
separately identified 
  
Author/ref Year Specimen 
type 
Number 
of cases 
CD 
Ileal CD Ileocolonic CD Isolated colonic CD  Ulcerative 
colitis 
Healthy 
controls 
Conclusions 
Naftali133 2016 Ileum and 
colon 
31 15 
Increased abundance 
of Escherichia and  
reduced 
Faecalibacterium; 
disease activity 
correlated with 
abundance of 
Fusobacterium 
8* 
Similar to colonic 
CD apart from 
Faecalibacterium 
abundance 2.7-
fold lower than in 
isolated colonic 
CD (not 
significant) 
 
8* 
Higher levels of 
Faecalibacterium 
and 2 unidentified 
genera of the 
Clostridiales and 
Ruminococceaea; 
lower levels of 
Enterobacteriaceae 
compared with ileal 
NA NA Ileal CD and colonic 
CD microbiomes 
distinct 
 
Haberman13
4 
2015 Ileal 
biopsy 
243 
(Paediat
ric) 
180 
Persistent reduction in Lachnospiraceae, 
Bifidobacteriaceae, Clostridiales, and 
Erysipelotrichaceae in all forms of CD, with 
expansion of Veillonellaceae, 
Pasteurellaceae, Neisseriaceae, 
Gemellaceae, Fusobacteriaceae, and 
Enterobacteriaceae 
 
 
63 
Persistent reduction 
in Lachnospiraceae, 
Bifidobacteriaceae, 
Clostridiales, and 
Erysipelotrichaceae 
in all forms of CD, 
with expansion of 
Veillonellaceae, 
Pasteurellaceae, 
Neisseriaceae, 
Gemellaceae, 
Fusobacteriaceae, 
and 
Enterobacteriaceae 
73 
Increased 
abundance 
of Firmicutes 
phyla 
43 
 
No difference 
between 
ileal/ileocolonic CD 
and colonic CD 
microbiome  
 
Lopez-
Siles132 
2014 Ileum and 
colon 
45 19 
Reduction in F. 
prausnitzii, E. coli 
moderately increased. 
13 
Reduction in  F. 
prausnitzii 
13 
F. prausnitzii 
comparable to UC; 
E. coli commoner 
than UC particularly 
in ulcerated zones 
28 
F. prausnitzii 
abundance 
intermediate 
between CD 
and HC. 
28 F. prausnitzii/ E. coli 
(FE index)‡ allowed 
differentiation 
between ileal CD and 
other CD 
phenotypes. 
Microbiota changes 
in colonic CD 
intermediate 
between ileal CD and 
UC. 
Willing#130,13
1 
2009,
2010 
Ileum and 
colon 
14 6 
Increased 
Enterobacteriaceae 
and  Ruminococcus 
gnavus;  decreased 
Faecalibacteria and 
Roseburia and 
compared to healthy 
controls. Increased E. 
coli. 
 8 
No reduction in 
Faecalibacterium or 
Roseburia. Some 
increase in E. coli 
but less marked 
than ileo-colonic. 
 6 Colonic CD 
microbiome 
intermediate 
between ileal CD and 
healthy controls. 
Baumgart129 2007 Ileum 29 13 
Increased abundance 
of Enterobacteriaceae, 
(E. coli, Shigella) 
reduction in  
Lachnospiraceae, 
(Ruminococci, 
Roseburia and 
Coprococci) and 
Clostridiales ( 
Faecalibacteria and 
Subdoligranula) 
8 
Results not 
presented 
separately 
8 
Enterobacteraciae 
not increased and 
Faecalibacteria not 
reduced. 
NA 7 
 
Ileal CD and colonic 
CD microbiome were 
distinct. Colonic CD 
more closely 
resembled healthy 
controls 
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Author/Ref N (isolated colonic 
CD) 
5ASA Placebo P value Conclusions 
Singleton140 64 CDAI mean change: 
-77 (+/-27) at 2g/day 
-81 (+/-31) at 4g/day 
CDAI mean change 
-52 (+/-31) 
Overall <0.01 for 
mesalazine vs 
placebo in all CD, 
P=0.42 for 
difference in ileal vs 
ileocolonic vs 
colonic 
High placebo 
response rate in 
isolated colonic 
CD so NS if this 
group taken alone; 
better response in 
ileal only disease 
 (a) Placebo-controlled trials of oral 5-aminosalicylic acid in isolated colonic Crohn’s disease 
(i) induction 
 
 
Author/Ref N (isolated colonic 
CD) 
5ASA relapse rate 
12months  
Placebo relapse 
rate 12 months 
P value Conclusions 
International141 56 32.1% 
(9/28) 
38.9% 
(11/28) 
0.49 5ASA only showed 
benefit in ileal 
disease 
Prantera142 18 40% 
(2/5) 
55% 
(6/?11) extrapolated 
from table 
NS 5ASA only showed 
benefit in ileal 
disease 
Gendre143 48 - - - 5ASA better 
(P<0.003) than 
placebo in all CD 
patients in remission 
<3m at onset, no sig 
difference according 
to disease location  
De Franchis144 36 45% 
(8/17)(extrapolated 
from figure) 
45% 
(9/19) 
1.0 5ASA ineffective in 
ileal, colonic, or 
ileocolonic 
 
 
(a) Placebo-controlled trials of oral 5-aminosalicylic acid in isolated colonic Crohn’s disease 
(ii) maintenance 
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Author/Ref N (isolated colonic 
CD) 
Sulphasalazine 
remission 
Placebo  
remission 
P value Conclusions 
Singleton146 20 - - NS Both groups also 
received tapering 
prednisolone. 
Placebo better 
than 
sulphasalazine in 
patients with ileal 
disease. 
Summers147 17 - - 0.006 
(comparison of 
outcome ranks) 
Sulphasalazine 
better than 
placebo in colonic 
CD (also effective 
in ileocolonic but 
not ileal only) 
Malchow148 27 31% 
(4/13) 
14% 
(2/14) 
0.4 NS for remission 
but P<0.01 for 
effect when judged 
by “failure and 
relapse” 
 
 (b) Placebo-controlled trials of oral sulphasalazine in isolated colonic Crohn’s disease (i) 
induction 
 
 
Author/Ref N (isolated colonic 
CD) 
Sulphasalazine 
relapse rate 
12months  
Placebo relapse 
rate 12 months 
P value Conclusions 
Singleton146 20 - - NS Sulphasalazine not 
significantly different 
from placebo in CD 
overall and no 
relation to disease 
location  
Summers147 19 - - NS No significant effect 
(judged by outcome 
rank based on 
CDAI) 
 
 
(b) Placebo-controlled trials of oral sulphasalazine in isolated colonic Crohn’s disease (ii) 
maintenance 
 
 
 
Author/Ref N (Isolated colonic 
CD) 
Olsalazine relapse 
/failure rate 12 
months 
Placebo relapse 
/failure rate 12 
months 
P value Comments 
Mahmud145 145 65.4% 53.6% 0.035 (Olsalazine 
worse) 
Olsalazine induces 
diarrhea, no 
evidence of efficacy 
 (c) Placebo-controlled trial of olsalazine in isolated colonic Crohn’s maintenance 
 
Table 6. Trials of 5ASA preparations where data presented separately for isolated colonic 
Crohn’s disease. 
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Author/Ref N (isolated 
colonic CD) 
Comparator Primary end 
point 
Rifaximin remission 
rate 
Placebo 
remission rate 
P value Conclusions 
Prantera152 190 active; 
76 placebo 
(from 
supplement 
table 2) 
Placebo Week 12 
remission 
(CDAI <150) 
3 doses: 400mg bd; 
800 mg bd; 1200 
mg bd; no dose 
response overall;  
pooled doses 
remission in 96/190 
(51%) 
28/76 (37%) 0.04 Rifaximin more 
effective for 
colonic than 
ileal disease 
(a) Controlled trial of oral rifaximin  
 
 
Author/Ref N (isolated 
colonic 
CD) 
Comparator Primary end 
point 
Metronidazole 
response rate 
Placebo 
response rate 
P value Conclusions 
Blichfeldt153 6 Placebo 
(crossover) 
Week 8 
response 
100% ? NS overall Metronidazole 
1g daily 
improved 
symptoms 
and lab 
values in all 
six with 
colonic 
disease 
Sutherland154 12  
(4 received 
10 mg/kg; 
4 received 
20mg/kg;  
placebo) 
Placebo Week 16 
response 
Mean CDAI drop 
145, 95% CI 26-
265, n=8 
CDAI 
increased by 
mean of 61, 
n=4 
0.05 Metronidazole 
more effective 
than placebo 
in colonic and 
ileocolonic 
disease but 
not small 
bowel disease 
 
(b) Controlled trials of oral metronidazole  
 
 
Table 7. Trials of antibiotics where data provided separately for patients with isolated 
colonic Crohn’s disease. 
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Author/Ref N 
(isolated 
colonic 
CD) 
Budesonide/ 
Comparator 
Primary 
end point 
Budesonide 
remission 
rate  
Comparator 
remission 
rate 
P 
value 
Steroid related 
adverse events 
Conclusions 
Tromm157 50 (distal 
colon 
excluding 
rectum) 
of 307 in 
trial 
Budesonide 
9mg od vs 
3mg tds vs  
Mesalamine 
1.5g tds 
Week 8 
remission, 
CDAI≤150 
23/30 
(76.7%)  
10/20 
(50%)  
0.051 Only 1 budesonide 
patient with acne, 
no other steroid-
related events 
Budesonide 
borderline signif 
better than 
mesalamine 
Bar-Meir158 27 of 201 
in trial 
Budesonide 
9mg od vs  
Prednisone 
40mg od 
2wks then 
taper 
Week 8 
remission, 
CDAI≤150 
2/10 (20%) 10/17 
(58.8%)  
0.1 67% Prednisone vs 
44% Budesonide  
Trend towards 
better efficacy in 
colonic disease 
with Prednisone, 
similar efficacy if 
small bowel 
involved.  
(a) Controlled trials of pH-modified release oral Budesonide  
 
 
Author/Ref N 
(isolated 
colonic 
CD) 
Prednisone/Comparator Primary 
end point 
Prednis(ol)on
e remission 
rate  
Comparator 
remission rate 
P value Conclusion
s 
Summers146 34 of 295 
in trial 
(Pt1) 
Prednisone up to 60mg 
/day (n=8) vs 
Azathioprine 2.5 mg/kg 
(n=9) vs 
Sulfasalazine 1g/15kg 
(n=8) vs 
Placebo (n=9) 
Week 17 
remission 
Data 
presented as 
rank outcome 
Data 
presented as 
rank outcome 
0.465 Prednisone 
not effective 
in colon 
only 
disease 
(but only 
n=8 treated) 
Malchow147 49 of 215 
in trial 
(inductio
n data 
from 
table 11) 
Sulfasalazine or 
combination of 
sulfasalazine and 6-
methyl Prednisolone 
Remissio
n by week 
18 
6/8 (75%) Placebo 2/14 
(14%) 
Sulphasalazin
e 4/13 (31%) 
Combination 
13/14 (93%) 
<0.01 for 
Sulfasalazine and 
6-
methylprednisolon
e and <0.001 for 
combination 
All active 
treatments 
better than 
placebo but 
combination 
superior to 
either agent 
alone 
 
 
(b) Controlled trials of oral Prednis(ol)one  
 
Table 8. Trials of oral corticosteroids where data provided separately for isolated colonic 
Crohn’s disease. 
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Author Year Type of 
study 
Study agent Total 
number of 
patients 
Number 
with 
colonic 
CD 
Endpoint Main findings P value 
(for 
colonic vs 
other sites 
unless 
stated) 
Conclusion 
Sandborn165 2011 RCT Certolizumab 
pegol (CZP) 
338 120 Week 6 
remission 
(CDAI 
</=150) 
23/63 (36.5%) 
CZP vs 10/57 
(17.5%) 
placebo  
0.052 
(colon vs 
other 
locations);  
0.034* 
(active vs 
placebo)  
Probable 
efficacy in 
colonic 
disease 
Arnott166 2003 Cohort Infliximab 74 26 Week 4 
response 
(fall in HBI 
by >3) 
23/26 (88%) 
response in 
colonic vs 6/11 
(54%) in ileal 
0.042 Better 
efficacy in 
colonic than 
ileal 
Laharie167 2005 Cohort Infliximab 44 18 Week 8 
response 
(fall in CDAI 
by >/= 100) 
83.3% colonic 
CD vs 50% 
ileal/ileocolonic 
0.03 Better 
efficacy in 
colonic than 
combined 
ileal/ileocolo
nic 
Vermeire168 2002 Cohort Infliximab 240 89 Week 4 
(luminal) or 
week 10 
(fistulising) 
response 
(fall in CDAI 
by >/=70 or 
50% 
decrease in 
draining 
fistulae 
81% response 
colonic CD vs 
55% ileal CD 
vs 74% 
ileocolonic 
OR 1.905, 95% 
CI 1.010 – 
3.597 
0.046 Better 
efficacy in 
colonic than 
combined 
ileal/ileocolo
nic. 
Remission 
also more 
likely in 
isolated 
colonic 
(P=0.019) 
Dupont-
Lucas169 
2016 Cohort 
 
Infliximab 248 
(children) 
63 Loss of 
response to 
maintenance 
therapy 
(moderate or 
severe 
global 
assessment 
requiring 
cessation of 
therapy) 
Colonic 25/54 
(46%) 
responders or 
remitters vs 
ileal/ileocolonic  
148/185 (80%). 
iHR 2.72 (95% 
CI 1.30-5.71) 
for loss of 
response in 
isolated colonic 
CD vs other 
sites 
0.008 Isolated 
colonic 
disease 
more likely to 
lose 
response 
Cohen170 2012 Cohort Adalimumab 75 15 Time to dose 
escalation 
13.2 weeks for 
colonic vs 34.6 
weeks for other 
sites 
0.0062 Isolated 
colonic 
disease 
required 
earlier dose 
escalation 
Sandborn 171 2013 RCT Vedolizumab 1115 316 (273 
active, 43 
placebo) 
Subgroup 
analysis 
based on 
62 active 
and 43 
placebo. 
Remission 
(CDAI 
</=150) at 
week 6 over 
placebo, 
Response 
(CDAI fall 
>/=100) 
week 6 
Remission 
difference from 
placebo: 5.9% 
for colonic vs 
6.7% for ileal 
vs 8.9% for 
ileocolonic 
Response: 
10.6% for 
colonic vs 
minus 10.4% 
for ileal vs 
7.1% for 
ileocolonic 
0.30 
remission 
 
 
 
 
 
0.23 
response 
No 
difference 
between 
isolated 
colonic and 
other 
Crohn’s for 
induction 
with 
vedolizumab 
Sandborn171  2013 RCT Vedolizumab 461 117 Remission at 
week 52 
over placebo 
Remission 
8wkly vedo: 
18.9% 
difference from 
placebo for 
colonic vs 
11.8% for ileal 
0.11 
 
 
 
 
 
0.19 
No 
difference 
between 
isolated 
colonic and 
other 
Crohn’s for 
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 36
vs 19.9% for 
ileocolonic 
Remission 
4wkly vedo: 
12.7% for 
colonic vs 
25.4% for ileal 
vs 12% for 
ileocolonic 
maintenance
with 
vedolizumab 
Table 9: Randomized controlled trials (RCTs) and cohort studies of biological therapy in 
Crohn’s disease where data were provided separately for patients with isolated colonic 
disease.  
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Author/ref Year Nature 
of 
study 
Adults/ 
children 
n= Intervention Duration Primary 
endpoint 
Results in 
patients 
with ileal 
involvement 
Results in 
isolated 
colonic CD 
P* 
Lochs177 1991 RCT Adults 55 (enteral 
nutrition; 9 
colon only); 
52 drug 
treatment 
Exclusive 
Peptisorb 
(oligopeptid
e diet) 
4-6 
weeks 
Remission 
(CDAI 
reduced by 
40% or 100 
points) 
 
Mean time 
till 
remission 
26 days 
Mean time 
till 
remission 
31 days 
NS 
Wilschanski178 1996 Retros
pective 
cohort 
Children 
7-17 
 
65 (5 colon 
only) 
Exclusive 
Amino-acid 
or peptide 
4weeks 
or more 
Remission 
PCDAI 
</=20 
Remission 
47/60  
(78%) 
Remission  
1/5 (20%) 
0.02 
Afzal179 2005 Prospe
ctive 
cohort 
Children 
8-17 
65 
(14 colon 
only) 
Exclusive 
polymeric 
8weeks Remission 
PCDAI<20 
Remission 
43/51 
(84%) 
Remission  
7/14 (50%) 
0.01 
Buchanan180 2009 Prospe
ctive 
cohort 
Children 
Median 
age 12 
110 (19 
colon only) 
Exclusive 
polymeric 
(Modulen) 
in 105, 
elemental 
in 5 
8 weeks Remission 
(improvt in 
all domains 
of global 
assesst)  
Remission 
73/91 
(80.2%) 
Remission 
15/19 
(78.9%) 
NS 
Rubio181 2011 Retros
pective 
cohort 
Children  
Mean age 
11 
106 (26 
colon only) 
Exclusive 
polymeric 
(Modulen) 
8 weeks Remission 
PCDAI<10 
Remission 86/106  (81%) 
overall, colonic data not 
presented separately but 
site not correlated with 
outcome 
NS 
De Bie182 2013 Retros
pective 
cohort 
Children  
Median 
age 14 
76 (18 
colon only) 
Exclusive 
polymeric 
or semi-
polymeric 
6 weeks Remission 
defined as 
no diarrhea, 
pain or wt 
loss 
Remission 
32/51 
(63%) 
Remission 
8/15 (53%) 
NS 
 
 
Table 10. Results of exclusive enteral nutrition as primary therapy in Crohn’s disease where data 
provided separately for isolated colonic Crohn’s disease. 
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 38
 Ileal/Ileocolonic 
Crohn’s disease 
Isolated colonic 
Crohn’s disease 
Ulcerative colitis 
Sex Slightly commoner in 
females (c55%)  
Commoner in females 
(c65%) 
Equal or slight male 
predominance  
Genetics Crohn’s-associated  
genotype including 
NOD2/CARD15 
Genotype midway 
between Crohn’s and 
UC 
Associated with HLA-
DRB1*01:03 but not 
NOD2/CARD15  
UC-associated 
genotype including 
HLA-DRB1*01:03 
Smoking Marked association  
Worsens prognosis 
Weak association  
Possibly worsens 
prognosis 
Marked negative 
association  
Oral contraception Positively associated Positively associated Positively associated 
(mainly in smokers) 
Serology ASCA commonly 
positive 
pANCA usually 
negative 
ASCA less commonly 
positive than 
ileal/ileolonic CD 
pANCA positive in 
minority 
ASCA usually negative 
pANCA commonly 
positive 
Mucosa-associated 
Microbiota 
Marked changes 
commonly including 
increased 
Proteobacteria (eg E. 
coli) and Fusobacteria, 
reduced Firmicutes (eg 
F. prausnitzii 
Intermediate changes 
similar to ileal/ileo-
colonic CD but less 
consistent 
Modest changes, 
including slight 
increase in E. coli but 
no reduction in F. 
prausnitzii 
Response to 
mesalazine 
No efficacy No efficacy Good efficacy 
Response to anti-TNF Good efficacy Good efficacy – 
probably better than 
for ileal/ileocolonic 
 
Good efficacy 
Response to excusive 
enteral nutrition 
Good efficacy Probably good efficacy 
but mixed reports 
No efficacy 
Surgery rate and 
type 
Required in majority Required in minority 
Segmental colectomy 
effective 
High failure for pouch-
anal reconstruction  
Required in minority 
Segmental colectomy 
not effective 
Low failure for pouch-
anal reconstruction 
 
 
 
Table 11. A summary of the distinguishing features of the three inflammatory bowel 
diseases: ileal/ileocolonic Crohn’s disease, isolated colonic Crohn’s disease, ulcerative colitis. 
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